Role of T Regulatory Cells in Pathogenesis of HIV-2 Infection by Zaidi, Irfan ul Hassan
Open Research Online
The Open University’s repository of research publications
and other research outputs
Role of T Regulatory Cells in Pathogenesis of HIV-2
Infection
Thesis
How to cite:
Zaidi, Irfan ul Hassan (2011). Role of T Regulatory Cells in Pathogenesis of HIV-2 Infection. PhD thesis The
Open University.
For guidance on citations see FAQs.
c© 2011 The Author
Version: Version of Record
Copyright and Moral Rights for the articles on this site are retained by the individual authors and/or other copyright
owners. For more information on Open Research Online’s data policy on reuse of materials please consult the policies
page.
oro.open.ac.uk
O .C -^ r Y n C  TO.
Role of T regulatory cells in HIV-2 infection
Thesis submitted to Open University, U.K. in fulfillm ent of the  
requirement for the Doctorate of Philosophy in the field of Life
Sciences
Irfan ul Hassan Zaidi
AFFILIATED RESEARCH CENTRE: MRC Unit, The Gambia, PO Box 273, Atlantic Road, 
Fajara, The Gambia, West Africa
Director of Studies: Dr. Assan Jaye, PhD.
MRC Unit, The Gambia
Supervisor: Prof. Hilton Whittle 
MRC Unit, The Gambia
bAT'c.-: rv'nss> 'o n  • \*3> Jouy 2.o 11
lion -£ op A to a p j>: <2 Sce~nS m B -2 R —o 1 1
July 2011
1
ProQuest Number: 13837550
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 13837550
Published by ProQuest LLC(2019). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346
Abstract
Infection with the HIV-2 virus can result in progression to acquired immunodeficiency 
syndrome (AIDS) similar to that seen in HIV-1 infections. However, the majority of HIV-2 
infected individuals do not show evidence of disease progression and maintain a 
functional immune system. It was hypothesized that there was a better balance between 
effector and regulatory responses in HIV-2 infection that contributed to virus control and 
immune activation. Furthermore, the role of T regulatory cells was investigated in the 
development of Immune Reconstitution Syndrome in HIV-1 and HIV-2 patients 
commencing antiretroviral therapy.
In the present study I first determined the appropriate immunological signature of Tregs 
in HIV infections. Tregs were defined on the basis of CD4+CD127lo/'FOXP3+ and were 
shown to be strongly correlated with CD4+CD25+FOXP3+ or CD4+FOXP3+ cells. However 
measurement of Tregs using flow cytometry and real time PCR did not correlate. Hence 
measurement of Tregs from whole blood using flow cytometry was used in subsequent 
studies.
HIV-2 infected subjects had a significantly lower percentage and absolute number of 
Tregs compared to HIV-1 infected individuals when matched by CD4 count. In both 
infections, Treg percentage increased as CD4 T cell count declined while the absolute 
level was positively correlated with CD4 T cell count. In addition the percentage levels of 
Tregs positively correlated with the immune activation and viral load in HIV-2 infection 
only.
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The next study measured the level of HIV specific immune responses and immune 
activation in asymptomatic HIV-1 and HIV-2 patients. HIV-2 infected subjects showed 
much higher percentage levels of HIV specific CD4 and CD8 T cell and lower percentage 
levels of activated T cells. Furthermore, it was shown that Tregs in HIV-2 patients were 
functional as their depletion resulted in increased HIV specific immune responses from 
CD4 and CD8 T cells.
To assess whether Tregs contributed to the development of Immune Reconstitution 
Inflammatory Syndrome, HIV-1 and HIV-2 infected patients that were scheduled to 
commence antiretroviral therapy were recruited and followed up for six months. 
Longitudinal measurement of Tregs showed no differences in the magnitude or trend of 
percentage or absolute numbers in patients that developed IRIS compared to those that 
did not.
Collectively these results suggest that the balance between effector and regulatory 
responses is maintained in HIV-2 infections which may in turn contribute to the improved 
prognosis of these patients compared to HIV-1 infections. The IRIS study showed that 
Tregs did not influence the development of IRIS though further functional 
characterization of these cells is required.
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Chapter 1: Introduction
The HIV epidemic continues to spread across the globe despite intense efforts to curb its 
transmission. The recent UNAIDS report (2010) estimates that there were 33.3 million 
people who were living with HIV and 2.6 million of these were newly infected. Sub- 
Saharan Africa continues to bear a disproportionally high burden of disease (Figure 1.1), 
with 1.8 million new infections in 2009 which represents almost seventy percent of all 
new infections in this period. Furthermore, of the 1.8 million AIDS related deaths globally,
1.3 million of these were in sub-Saharan Africa. The predominant mode of transmission in 
sub-Saharan Africa is heterosexual transmission and vertical transmission to breastfed 
infants. While the number of transmissions in 2009 represents a decline of the peak 
transmission period in 1999, the scale of the problem remains vast and requires 
concerted efforts to control transmission of the HIV virus.
The introduction of antiretroviral therapy (ART) in many countries has resulted in a sharp 
decline in AIDS related deaths. However it is estimated that currently in low income 
countries only thirty six percent of those needing ART have access to this life saving 
therapy. Hence, the use of ART alone cannot curtail the HIV epidemic as the worst 
affected regions are also some of the poorest, which means that the economic cost on 
the health infrastructure of these countries makes universal ART access unsustainable. 
The development of an effective vaccine against HIV infections would provide a huge 
boost to curb its further spread.
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Fig 1.1: Global prevalence of HIV infection 2009 (UNAIDS Report on the Global AIDS 
epidemic 2010)
HIV-1 was identified almost twenty years ago followed soon after by the identification of 
a second retrovirus, HIV-2, that can also cause AIDS. The HIV epidemic has been primarily 
driven by the spread of HIV-1 but to a lesser degree by HIV-2, that is estimated to have 
infected approximately 1 million cases. HIV-2 was first isolated in 1986 from two AIDS 
patients from West Africa who repeatedly tested seronegative for HIV-1 (Clavel et al, 
1986). Both viruses preferentially infect CD4 T cells, integrate into the host genome and 
upon cellular activation, use the host cell machinery to produce multiple copies which 
then bud out of the cell and infect new target cells.
The origin of HIV-1 and HIV-2 is thought to be as a result of cross species transmission of 
Simian Immunodeficiency Viruses (SIV) from Chimpanzees (SIVcpz) and Sooty Mangabeys 
(SIVsm) respectively. It estimated that such cross species transmissions of SIVsm to
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human populations has occurred on at least eight separate occasions giving rise to eight 
HIV-2 groups. Of these only HIV-2 Group A and B have become endemic, while the other 
groups represent single person infections (reviewed by Hahn et oi, 2000 and Damond et 
a i, 2004).
HIV-2 infections are primarily confined to West Africa, while HIV-1 has spread all over the 
world (See Section 2.7 for more details). Though the initial study of HIV-2 infections in a 
sex worker cohort in Senegal suggested that the virus was non-pathogenic, this was 
found not to be the case for AIDS was described in singly infected HIV-2 patients. The 
majority of HIV-2 subjects are regarded as long term non-progressors because they 
maintain high levels of CD4 T lymphocytes accompanied by low or undetectable levels of 
plasma viremia (Berry et al., 1998). However, a small percentage of HIV-2 patients 
progress to AIDS, which is indistinguishable from HIV-1 induced immunodeficiency. These 
patients exhibit a high plasma viral load compared to those with non-progressive HIV-2 as 
well as a higher degree of systemic immune activation (Leligdowicz etal., 2009).
It is important to determine the factors that contribute to disease progression in HIV-2 
and the underlying mechanisms responsible for slow or non-progression of disease in so 
many HIV-2 infected subjects. This is important for strategies to design 
immunotherapeutic and control measures against HIV infection.
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Immune response in HIV-2 infection
Many current studies are examining the role of both cellular and humoral immunity in 
controlling HIV-2 infection. The cellular immune response has been demonstrated to be 
a pivotal factor in controlling viral replication. Initial studies showed that during the acute 
phase of infection, a rise in the CD8 T cell response against viral epitopes coincided with a 
decline in peripheral viral loads (Ogg et al., 1998). Further evidence of the importance of 
cell mediated immune responses came from experimental SIV infection in monkeys, 
which showed that ablation of CD8 T cells resulted in a failure to control viral replication 
during the acute phase of the infection (Schmitz et al., 1999). An early study 
demonstrated that vigorous CD8 specific T cell response was established against Gag 
antigens in HIV-2 infection (Gotch et al, 1993). HIV-2 specific CD8 T cells are more 
polyfunctional compared to those found in HIV-1 specific cells and this polyfunctionality 
translates to higher levels of cytokine production on a per cell basis (Duvall et al, 2008). 
The importance of these responses was recently highlighted in a study of HIV-2 infected 
subjects recruited from a community cohort which showed there was an inverse 
correlation between CD8 T cell IFN-y responses targeted towards epitopes in the Gag 
protein and viral load (Leligdowicz et al, 2007), suggesting that specific cellular immune 
responses account for viral control in HIV-2 infection.
The quality of CD4 T helper responses, essential for efficient CD8 T cell response, was also 
found to be strikingly different in HIV-1 and HIV-2 infections (Duvall et al., 2006). 
Whereas HIV-2 specific CD4T cell activity showed preserved polyfunctional responses (IL- 
2 and IFN-y secretion) in patients with conserved CD4 T cell counts, such responses were 
absent in HIV-1 patients at a similar stage of disease. Innate immune responses also 
appeared superior in HIV-2 infection as NK cell activity was also found to be greater in
asymptomatic HIV-2 subjects with high CD4 T cell counts than in similar HIV-1 patients.
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These differences disappeared in patients showing signs of disease progression (Nuvor et 
al, 2006). Hence, the immune response directed towards HIV-2 seems effective in 
controlling HIV-2 replication and may account for differences in plasma viremia between 
HIV-1 and HIV-2 infections despite a similar proviral load (Berry et al., 1998 ). However, 
HIV-2 can result in disease progression similar to that seen in HIV-1 infection and there 
are few studies to explain the factors that diminish these responses and lead to loss of 
viral control.
Immune activation in HIV pathogenesis
HIV-1 and HIV-2 infections are characterized by chronic and high levels of activation of 
the immune system. High immune activation levels have been shown to be predictive of 
disease progression in both HIV-1 and HIV-2 (Deeks et al., 2004, Giorgi et al., 1999, Hunt 
et al., 2008, Jaffar et al., 2005). However, whether immune activation levels differ 
between the two infections remains unclear. One study comparing immune activation 
levels in HIV-1 and HIV-2 patients adjusted for CD4 counts showed no differences (Sousa 
et al 2002) despite significantly lower viral loads in HIV-2 patients. In contrast, HIV-2 
infected sex-workers in Senegal showed significantly lower levels of activated T cells 
compared with their HIV-1 infected counterparts (Hanson et al., 2005). A more recent 
study showed that immune activation consistently correlated with viral load in HIV-2 
subjects from a community cohort in Guinea-Bissau (Leligdowicz et al., 2010). This 
suggests that curbing immune activation is essential for survival of HIV-2 infected 
individuals. However, there remains no data on how the immune system is able to 
counter activation in HIV-2 infections so this requires attention.
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T regulatory cells in HIV infection
The description of a subset of T cells which behave as regulators of the immune system, 
was suggested almost four decades ago, but received little support due to the failure to 
describe their cellular phenotype. While earlier researchers focused on defining 
suppressive CD8 T cells, the description of a subset of CD4 T cells (aptly termed T 
regulatory cells) that expressed the a-chain of the IL-2 receptor (CD25), were shown to 
have suppressive potential in both mice and humans (Sakaguchi et al., 1995; Baecher- 
Allan et al., 2001). These cells were shown to be a committed lineage of CD4 T cells that 
were thymically derived and hence came to be known as natural Tregs. The constitutive 
expression of the transcription factor Forkhead Box Protein 3 (FOXP3) is a feature of 
natural Tregs and its activity is required to maintain their suppressive phenotype. Natural 
Tregs modulate both cytokine secretion and proliferative responses from effector cells 
after stimulation via their T cell receptor using a variety of mechanisms, which are both 
contact dependent and independent. Whether they assist or hinder the response against 
HIV-1 is an active topic of research. Earlier studies provided conflicting results on whether 
their frequencies were elevated or depleted during the course of HIV infection. This was 
mainly due to the inconsistencies in cellular phenotype, methods used to define their 
numbers and sampling of heterogeneous population of patients with regards to disease 
progression. In addition, several studies did not consider the effects of antiretroviral 
therapy on the Treg population in HIV-1 infected patients. Hence, while some studies 
have concluded that Tregs play a detrimental role during HIV disease progression by 
inhibiting HIV specific immune responses (Kinter et al., 2004; Weiss et al; 2004), others 
have contended that their ability to control immune activation means their activity and 
presence is required to prevent disease progression (Eggena et al., 2005; Ndlovu et al., 
2007).
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Studies characterizing the frequency and function of Tregs in HIV-2 infections alone or in 
parallel with HIV-1 infections are scarce. This study compared the levels of Tregs in HIV-2 
patients in parallel with HIV-1 patients at similar stages of disease progression that were 
enrolled in the Fajara cohort at the Medical Council Laboratories in The Gambia.
The first aim was to decipher the optimal methods to enumerate Tregs (Chapter 4), and 
then measure the levels of these cells in HIV-2 infections compared with HIV-1 infected 
individuals and the relationship with systemic immune activation and viral loads (Chapter 
5). The next part of the study was to compare the T cell effector responses in 
asymptomatic HIV-1 and HIV-2 infections and relate these to immune activation levels 
(Chapter 6). Finally, the last arm of the study investigated the dynamics of Tregs in HIV-1 
and HIV-2 patients after initiation of antiretroviral therapy and their possible involvement 
in Immune Reconstitution Inflammatory Syndrome (Chapter 7).
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Chapter 2: Literature review
2.1 Biology of HIV-1 and HIV-2
HIV-1 was shown to be the causative agent of AIDS by Francoise Barre-Sinoussi's team 
and was quickly confirmed by other research groups (Barre-Sinoussi et al., 1983; Gallo et 
al, 1984; Levy et al., 1984). A second related virus, HIV-2 was later isolated in 1986 from 
two AIDS patients from West Africa who repeatedly tested seronegative for HIV-1 (Clavel 
et al, 1986).
HIV-1 and HIV-2 represent the only two retroviruses known to infect humans and cause 
AIDS. Free virion particles viewed under an electron microscope possess a cone shaped 
core composed of the viral p24 Gag capsid protein and are approximately 100-120 nm in 
diameter. The genome of the viruses consists of two identical strands of single stranded 
RNA approximately 9.8 Kilobases. This encodes three major proteins; Group Specific 
Antigen {gag), Envelope (Env) and Polymerase (pol), as well as accessory proteins 
Regulator of Virion {Rev),Trans activator of Transcription {Tat), Viral Infectivity Factor 
(Vif), Viral Protein R{Vpr) , Viral Protein U (Vpu) and Negative regulatory factor(/Ve/J 
(Figure 1.2). The HIV-2 viral genome does not contain the Vpu gene and instead has the 
Viral protein X {Vpx) gene. The designation of these proteins and their functions are listed 
in Table 1.1. HIV-1 and HIV-2 share significant homology especially in the gag and pol 
regions (60%) but less so for other genes.
The gag gene encodes for a large polyprotein designated Pr55Gog that is proteolytically 
cleaved by the viral protease to yield mature Gag proteins Matrix (MA or pl7), Capsid (CA 
or p26 for HIV-2, p24 for HIV-1), nucleocapsid (NC or p7 for HIV-2, p6 for HIV-1). The pol 
encoded proteins are protease (PR), reverse transcriptase (RT) and integrase (IN), which 
are transcribed as a large polyprotein precursor designated Prl60GagPo1 and cleaved by 
viral PR. The envelope glycoproteins are also synthesized as a polyprotein precursor,
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gpl60, which is cleaved by cellular proteases to yield the surface and transmembrane 
glycoproteins gpl20 and gp41 respectively.
Gag p24,pl7,p7,p7 Capsid protein, structural
Env gpl20,gp41 Envelope surface protein
Pol p66,p51 Reverse transcriptase
Rev pl9 regulation of viral mRNA expression
Tat pl4 Transactivation
Vif p23 Assists in proviral DNA synthesis and/or virion assembly
Vpr pl5 Assists in virus replication; Transactivation
Vpu pl6
Helps in virus release by disrupting cell-virion 
interactions; only present in HIV-1
Nef P27
Downregulation of MHC molecules on surface of infected 
cells;
Vpx pl5 Helps in virus entry and infectivity; only present in HIV-2
Protease plO posttranslational processing of viral proteins
Integrase p32 Viral cDNA integration
Tev p26 Tat/Rev activities
Table 2.1: Gene products of HIV-1 and HIV-2 (adapted from HIV and Pathogenesis of AIDS 3rd 
Edition)
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Fig 2.1: Genome organization of HIV-1 and HIV-2 (http://www.hiv.lanl.gov)
2.2 Replication of HIV-1 and HIV-2
HIV-1 and HIV-2 infect lymphoid and myeloid cells that express the surface receptor CD4 
(Dalgleish etal., 1984; Klatzmann e ta l 2004; McDougal et al., 1986; Maddon etal., 1986) 
The viruses also require the presence of a second co-receptor, which assists viral entry. 
The primary co-receptors that are utilized by both HIV-1 and HIV-2 have been identified 
as C-C chemokine receptor 5 (CCR5) and C-X-C chemokine receptor 4 (CXCR4). However, 
HIV-2 exhibits higher promiscuity in co-receptor usage and can use CCR1, CCR3, CXCR2, 
CXCR4, BOB and BONZO in vitro, suggesting that it has the potential to target more 
diverse cell types. (Bron et al., 1997; McKnight et al., 1998; Guillon et al., 1998; Owen et 
al., 1998; Morner et al., 1999).
Infection of cells requires the interaction of viral gpl20 on the surface with the CD4 T cell
receptor target cells which triggers a conformational change on gpl20 and exposes the
binding sites for the chemokine co-receptors. This allows membrane fusion and
ultimately release of the viral core into the target cell. The viral core transports the
genome to the nucleus using the cellular microtubule network. In order to integrate into
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the human genome, the RNA is reverse transcribed to a proviral DNA by the viral enzyme 
RT. The viral genome is then integrated into the host genome and is flanked by noncoding 
long terminal repeats (LTR) which regulate the transcription of the integrated proviral 
genome. The initial steps in integration require the formation of a preintegration complex 
which consists of the viral DNA molecule, IN, MA, RT, NC as well as host proteins. (Miller 
et al., 1997, Bukrinsky et al., 1993). The IN enzyme binds to the LTR region and catalyzes 
the integration of the viral DNA into the host genome (Delelis et al., 2008).
Several studies have shown that the levels of proviral DNA of infected HIV-1 and HIV-2 
are similar and suggest that the ability of the two viruses to infect target cells and 
integrate into the host genomes is comparable (Ariyoshi et al., 1995; Popper et al., 2000; 
MacNeil et al., 2007).
Once integrated into host chromosomes, the proviral DNA serves as a template that 
encodes a full complement of structural, regulatory and accessory proteins required for 
virus replication. The HIV LTR serves as the transcriptional initiator and contains binding 
sites for host transcription factors NF-kB and Sp-1. The basal transcriptional activity of the 
LTR is very low and requires the presence of Tat for significant upregulation of viral RNA 
production (Pumfery etal., 2003; Romani etal., 2010).
Membrane enclosed HIV particles are generated as the virus hijacks the host cellular 
machinery to produce multiple copies of itself. The first step requires assembly of 
infectious viral particles that contain viral Env and the three structural proteins MA, CA 
and NC that are all generated from the Pr55 polyprotein. The NC protein recruits and 
packages the viral genome while the CA protein forms the capsid core that encloses this 
complex.
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The HIV virus needs to counter the inhibitory activities of intrinsic host restriction factors 
whose role it is to block the viral replication cycle. The host restriction factors that have 
been the most widely studied in the context of HIV-1 include apoplipoprotein B mRNA- 
editing enzyme-catalytic polypeptide-like 3G (APOBEC3G), Tripartite motif-containing 
protein 5a (TRIM-5a) and Tetherin. The respective function of these host restriction 
factors is a) introduction of lethal hypermutations in the virus genome (Sheehy et al 
2002), b) premature uncoating of the HIV capsid (Stremlau et al., 2006) and c) Prevention 
of budding of mature viruses from the host cell membrane (Neil et al., 2008).
The accessory proteins of HIV-1 play a major role in overcoming the inhibitory activities of 
these host restriction factors. The Vif protein targets the APOBEC3G protein for 
proteosomal degradation, while the Vpu, Env and Vpu proteins have been implicated in 
overcoming the activity of Tetherin. Also, the high variability seen in the capsid coat 
protein of the HIV-1 virus may allow escape from the activity of TRIM-5a.
Once successfully assembled and separated, individual virions separate from the cellular 
plasma membrane infect new target cells. The number of HIV-1 virions produced per day 
in the absence of antiretroviral therapy exceeds 10 billion (Perelson et al., 1996), which 
represents a significant pressure on the immune system and continuous infection of 
target CD4 T cells. The replication cycle of HIV is summarized in Figure 2.2.
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2.3 Clinical course of HIV infection
HIV-1 infection is characterized by three distinct clinical phases: acute, chronic and the 
AIDS phase. The acute phase manifests as flu like symptom (Kassutto et al., 2004) and 
during this time the virus replicates to high levels and leads to massive depletion of CD4+ 
T cells in mucosal tissues (Brenchley et al ., 2006). This triggers activation of the host 
immune system and induction of specific immune responses to the virus leads to 
lowering of the viral load to a set point. Thus an asymptomatic chronic state is 
established. In HIV-2 infection, little is known about the early events because of rare 
detection of incident cases.
The chronic phase is marked by a gradual decline of the CD4+ T cells in the periphery 
which correlates with an increase in markers of immune activation and plasma viral loads. 
The decline in CD4+ T cells can only partially be explained by direct virus effects, since 
only 1 in 10000 CD4 T cells in the periphery harbour viral proteins or mRNA (Fauci et al., 
1986). Immune activation steadily increases during the chronic phase and contributes to 
loss of CD4+ T cells, mediated through combination of direct killing by CD8+T cells, effect 
of loss of integrity of lymphoid tissues and increased induction of apoptosis.
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immune activation during the long-term course of HIV-1 infection (adapted from 
Grossman et al., 2006)
The chronic phase in HIV-2 infection is significantly longer than in HIV-1 infection and is 
characterized by maintenance of high CD4+ T cells accompanied by significantly lower 
viral loads (Berry et al., 2002; Jaffar et al., 1997; Berry et al., 1998).
In the absence of antiretroviral therapy, the host will eventually progress to the final 
stage of disease, AIDS. The CD4+ T cell levels drop below 350 cells/pl and this is 
accompanied by a dramatic rise in peripheral viremia and immune activation levels. 
Paradoxically, a profound state of immunosuppression is evident and the host eventually 
succumbs to opportunistic infections.
31
2.4 Treatment of HIV infections:
The absence of an effective prophylactic tool has heightened the need for therapeutic 
measures to reduce HIV induced mortality. In 1987, the first antiretroviral drug, a 
nucleoside analogue called azidothymidine (AZT), which targets the reverse transcription 
stage of the virus, was approved for use. Soon after, a number of different nucleoside 
reverse transcriptase inhibitors (NRTI) were introduced, some more toxic to the host than 
others. However, it soon became evident that the use of single therapies was ineffective 
as drug resistant mutations were reported within a year after the introduction of AZT.
A second class of drugs that also targeted the viral RT by blocking the active site of the 
enzyme (called non-nucleoside reverse transcriptase inhibitors (NNRTI)) were introduced 
and when used in combination with an NRTI, showed potent suppression of viral 
replication in HIV-1 patients. The introduction of Protease inhibitors (PI), which target the 
essential activity of the viral protease, was an important addition to the arsenal of drugs 
available to treat HIV infection.
A combination of three drugs (termed HAART) became the standard for treatment of 
HIV-1 patients as it helps circumvent the problem of rapid drug resistance. The current 
recommendation is for the use of two NRTIs and one NNRTI, since the currently available 
PI drugs show substantial toxicities. The introduction of HAART resulted in reduction of 
rate of progression and AIDS related deaths. In the majority of HIV patients commencing 
therapy, peripheral viremia drops below the limit of detection that is accompanied by 
substantial recovery of circulating CD4+ T cells and reduction in immune activation levels.
Treatment of HIV-2 infections is complicated because of variations within its genome that 
confer natural resistance to some protease inhibitors (Colson et al., 2004) and reduced 
sensitivity to NNRTIs (Witvrouw et al., 1999). This severely limits both the first and
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second line therapy options in these patients and requires careful monitoring to ascertain 
that HIV-2 infected patients on HAART respond favourably to therapy.
HAART therapy is a lifelong commitment and cessation of therapy results in a rebound of 
viral load levels resulting from re-initiation of viral replication from latent reservoirs. 
HAART therapy is recommended in patients whose CD4+ T cell counts have dropped 
below 350 cells/pl, though there remains some debate as to whether this cut-off should 
be raised. This is especially pertinent since it has been demonstrated that patients 
commencing HAART at low CD4 T cells counts are more susceptible to developing 
Immune Reconstitution Inflammatory Syndrome (IRIS) (Valin et al., 2010, Ratnam et al.,
2006).
2.5 Immune Reconstitution Inflammatory Syndrome
Immune reconstitution inflammatory syndrome (IRIS, also referred to as immune 
reconstitution disease (IRD)) occurs in patients commencing ART. This syndrome is 
characterized by a strong inflammatory reaction and is more common in patients 
commencing ART therapy with low nadir CD4 T cell count. The majority of patients with 
onset of IRIS show good response to ART therapy as witnessed by the suppression of 
viremia to undetectable levels and good recovery of CD4 T cell levels (French et al., 1999). 
The onset of IRIS typically occurs within the first three months after starting ART and it 
can affect adherence of patients to the therapy. Most patients resolve their symptoms 
but it can be fatal in a small number of patients.
IRIS has been broadly classified into paradoxical IRIS (exuberant immune response against 
residual antigens) or unmasking IRIS (caused by viable pathogens). While the causes of 
IRIS maybe due to a variety of different pathogens, IRIS associated with Mycobacterium 
tuberculosis (M tb) remains the most widely studied. Other pathogens associated with IRIS
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include cryptococci, Kaposi's sarcoma associated herpesvirus, cytomegalovirus (CMV), 
herpes zoster as well as Hepatitis B (reviewed by Sereti et al., 2010).
The definition of IRIS is still vague since it still relies on clinical exclusion of other factors 
that maybe causing the symptoms. In Mtb associated IRIS it has been demonstrated that 
higher levels of the T cell cytokine IFN-y at the time of IRIS compared to non-IRIS cases. A 
more recent study showed that highly activated memory CD4 T cells produced high levels 
of IFN-y after stimulation with Mtb derived purified protein derivative (PPD) (Bourgarit et 
al., 2006). With the increasing access of ART to HIV infected patients there is an urgent 
need to better define IRIS and understand the factors that may contribute to 
development of IRIS.
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2.6 Microbicides and vaccines for HIV infections
The use of microbicides, and development of prophylactic HIV vaccines, would be 
important weapons in combating the spread of the disease and significantly reduce HIV 
associated mortality. However, a number of microbicides that have reached phase 3 
testing failed to protect against HIV infection. This could be attributed to a lack of 
knowledge about the very early events at mucosal surfaces where the viral entry occurs. 
This is now an active area of research and may lead to development of better 
microbicides. There is however renewed hope in HIV biomedical prevention research 
following the success story of the phase IIB efficacy trial of Tenofovir as a microbicide in 
the CAPRISA004 trial in South Africa. Tenofovir is an adenosine nucleotide analogue and 
is a potent inhibitor of viral replication. Application of a microbicide gel containing 1% 
Tenofovir resulted in significantly lower incidence of HIV-1 infections in cases compared 
to the placebo group (Abdool Karim et al., 2010). Furthermore there was no evidence of 
development of Tenofovir resistant HIV-1 strains.
The development of HIV preventive vaccine is more elusive. Initial attempts to design a
vaccine against HIV-1 infection were focused on inducing neutralizing antibodies against
the viral protein gpl20, but this failed to protect volunteers from infection (Flynn et al.,
2005, Pitisuttithum et al., 2006). The emphasis shifted to designing vaccines that could
elicit a strong cytotoxic T cell response, with the hope that this would reduce viral load
and hence reduce transmission of the virus. The trial of the Merck vaccine candidate,
STEP, designed to elicit HIV specific T cell responses, was stopped early as subjects that
received the vaccine had higher infection rates than the control group (McElrath et al.,
2008). This failure may have been due to immune activation caused by the adenovirus 5
vector used in the vaccine construct (Buchbinder et al., 2008), though a recent report
found no evidence to link adenovirus 5 serostatus to activation within the CD4 T cell
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compartment (Hutnick et al., 2009). More encouragingly, the preliminary results of 
another vaccine trial (RV144) showed a modest reduction in HIV infection rates in 
vaccinated versus the placebo group. The vaccine efficacy was low (26.4%) and only 
significant after the removal of 7 subjects from the vaccinated group who were HIV 
positive at baseline (Rerks-Ngarm et al., 2009). The participants were primed with ALVAC 
HIV vaccine and boosted with HIV-1 gpl20 based AIDSVAX vaccine. These results have 
galvanized the HIV research community in the belief that a vaccine may yet be possible. 
However, there remains significant debate about the interpretation of the results of the 
study, as neither the viremia nor CD4 T cell counts differed in infected patients between 
the vaccinated or control patients that were infected (Rerks-Ngarm et al., 2009).
These results have highlighted the need to gain a better understanding of the basic 
biology of HIV infection and the role of immune activation during HIV infection (Barouch 
et al., 2008). Though the success in designing an effective vaccine has been limited, the 
information gleamed from these trials have yielded important clues for design of the new 
generation of vaccine candidates. Indeed, the consensus amongst the HIV research 
community since these trials has been to advocate a policy of 'back to basics approach7 
(reviewed by Jose Esparalda et al., 2009), which calls for a better understanding of the 
virus and the interplay with the host immune system.
There are fewer HIV-1 infected subjects who are long term non-progressors (LTNP). This 
has made it difficult to explore immune correlates of protection more fully and most 
initial vaccine designs have relied on animal models of SIV infection. The study of HIV-2 
infection, which often results in LTNP of disease, presents an excellent model to 
investigate the factors that constitute and influence a successful and balanced immune 
response.
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2.7 Epidemiology of HIV-1 and HIV-2 infection in West Africa
The HIV epidemic has been primarily driven by the spread HIV-1 but to a lesser degree by 
the related lentivirus HIV-2, which accounts for approximately 1 million cases. HIV-2 was 
first described in West Africa and subsequent cases were detected in India, Mozambique, 
Angola and Brazil and were attributed to links with the Portuguese who were former 
colonialists in Guinea Bissau, a country which has the highest HIV-2 prevalence (Poulsen 
et al, 1993). Thus HIV-2 infections are predominantly confined to West Africa. However, 
unlike the HIV-1 epidemic, which continues to spread globally, the incidence of HIV-2 
remains stable or is declining in many of the affected West African countries (van der 
Loeff et al., 2006). Longitudinal studies conducted in Caio, Guinea Bissau where the 
prevalence of HIV-2 was between 8-10 % in the 1980s, showed a decline to 4.7% in 2007 
in a community cohort. In stark contrast, the HIV-1 prevalence rose sharply in the same 
community from 0.5% in 1990 to 3.6% in 2007 (van Tienen et al., 2009). Similarly, the 
prevalence of HIV-2 in a sex worker cohort in Senegal fell from 8% in 1985 to 5.5% in 
2003, while HIV-1 prevalence increased from 1% to 13.8% in the same period (Hamel et 
al, 2007). The reasons for the decline in HIV-2 incidence could be primarily due to the 
lower transmission efficiency. Vertical transmission from HIV-2 infected breastfeeding 
mothers is only 4% which is six-fold less than that in HIV-1 infected mothers (O' Donovan 
et al, 2000 ). Sexual transmission is also less efficient as the amount of virus found in 
genital secretions was significantly lower than in HIV-1 infections (Gottlieb et al., 2006).
HIV-2 infection can result in AIDS similar to that observed in HIV-1 infections. Studies in a
clinical cohort in The Gambia (Schim van der Loeff et al, 2002) and in two community
cohorts in Guinea Bissau did however show that the mortality risk for HIV-2 infected
individuals was only two fold greater than uninfected controls (Poulsen et al., 1989,1993),
suggesting that HIV-2 was less pathogenic than HIV-1. The clinical features of HIV-2
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patients progressing to AIDS is virtually indistinguishable from HIV-1 patients except for 
the observation that HIV-1 patients were 12.5 times more likely to have Kaposi Sarcoma 
(Ariyoshi et al, 1998). Determining the factors that lead to disease progression in HIV-2 
patients would provide valuable information on how a mostly benign infection can lead 
to immunodeficiency that is as deadly as that seen in HIV-1 infection.
The definitive feature of HIV-2 infection in the majority of cases is characterized by 
significantly lower levels of circulating virus relative to HIV-1 patients with similar levels of 
CD4 T cell depletion, even though the amount of integrated virus is similar in both 
infections (Berry et al., 1998). A longitudinal community-based study of HIV-2 infections 
in Guinea Bissau showed that low and stable levels of peripheral viremia predicted a 
normal survival for infected individuals (van der Loeff et al., 2010). In addition, HIV-2 
infected individuals that showed little change in their viral load levels maintained high 
CD4 T cell counts (Berry et al, 2002).
Therefore, the lower level of peripheral viremia seen in most HIV-2 infections seems to 
explain the improved prognosis relative to HIV-1. While HIV-1 replicates to high levels and 
is readily detectable in the periphery, HIV-2 infected individuals maintain low to 
undetectable viral loads. This could be a result of the different replication kinetics of the 
two viruses, as demonstrated in vitro (Marchant et al., 2008), or due to better control of 
virus replication by host factors such as innate restriction factors and the immune 
response. The immune system, far from being a silent observer, is overly activated in HIV- 
1 and HIV-2 and it is a key factor in disease pathogenesis of both viruses.
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2.8 Immune activation in the pathogenesis of HIV-1 and HIV-2 infection
The hallmark of HIV pathogenesis is chronic aberrant immune activation, which in HIV-1
infection has been found to predict disease progression (Deeks et al 2004, Giorgi et al
1999, Hunt et al 2008 and Liu et al 1997). Immune activation is defined by elevated levels
of proinflammatory cytokine secretion (TNF-a, IL-6, IL-lp, M IP-la, M IP-ip and RANTES),
polyclonal B cell activation, increased T cell turnover, increased frequencies of cells with
an activated phenotype (usually defined by surface expression of CD38 and HLA-DR on T
cells) and secretion of (32-microglobulin and Neopterin. Immune activation is required in
the induction of specific immune responses against HIV antigens and control or clearance
of an invading pathogen. However, the HIV virus most efficiently infects activated CD4 T
cells. Indeed it has been shown that elevated immune activation increases viral
replication and infection of new target cells (Grossman et al, 1998). Conversely, viral
replication also results in increased levels of immune activation as witnessed by elevated
levels of CD25 and HLA-DR on bystander CD4 T cells, hence generating increased targets
for infection. More specifically, the expression of late activation markers HLA-DR, CD38 or
co-expression of both markers on CD4+ T cells were associated with increased viral
infection and subsequent apoptosis (Biancotto et al., 2008). Chronic immune activation
leads to increased T cells turnover and eventual exhaustion of the memory T cell pool and
may also lead to damage of thymic tissue required for T cell regeneration (Douek et al.,
1998, Schaker et al., 2006).
Multiple factors lead to establishment of immune activation and inflammation in HIV
infection. During primary infection, HIV-1 induces a strong CD8+ T cell response which
persists through to the chronic phase of the infection (Betts et al., 2001). The continuous
activation of CD8+ T cells could contribute to the loss of infected as well as uninfected
CD4+ T cells. In addition viral accessory protein Nef has been found to induce direct
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activation of lymphocytes, macrophages and production of cytokines in vitro, which may 
contribute to the excessive immune activation observed during HIV infection. 
Furthermore, HIV replication can also cause activation indirectly by depleting CD4+T cells 
which are required for the control of viruses such as CMV and EBV. Also, the 
proinflammatory environment generated after HIV-1 infection causes additional 
bystander activation of concurrent viral infections such as CMV and EBV (Papagno et al.,
2004).
The aberrant nature and extent of activation suggests that factors other than the direct 
viral stimulation are also involved. Indeed recent studies have shown that HIV infection 
at the mucosal lymphoid tissue leads to massive depletion of CD4+ T cells and disruption 
of the mucosal barriers (Brenchley et al, 2004). This results in increased microbial 
translocation through the leaky membranes and these microbial products cause 
activation of the innate immune system (Brenchley et al, 2006). The increased levels 
bacterial products such as lipopolysaccharide (LPS), flagellin and CpG DNA can activate 
macrophages and dendritic cells to produce a range of proinflammatory cytokines (IL-6, 
TNF-a and IL-ip). Indeed, a recent study showed that immune activation levels correlated 
with the levels of bacterial DNA in untreated HIV-1 infections, which were lower in 
treated HIV-1 infections (Jiang et al 2009). Furthermore the levels of soluble CD14 (LPS 
receptor) have been shown to independently predict mortality in a cohort of HIV-1 
infected individuals (Sandler et al., 2011). Taken together these data suggest that 
microbial translocation is indeed an important determinant of immune activation in HIV 
infected individuals.
Further evidence that immune activation is a pivotal factor in progression to AIDS has 
come from the study of non-pathogenic SIV infection in natural hosts such as sooty
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mangabeys and African green monkeys. Most infected animals live a normal healthy life 
in the wild and captivity (Silvestri et al, 2007). During the acute stage of infection, 
immune activation levels are high but subsequently decline even though there is active 
viral replication as witnessed by high level of viremia (104 — 106 copies/ml) ( Broussard et 
al 2001). Thus, the ability of these primates to remain asymptomatic lies in their ability to 
down regulate immune activation despite lack of viral control.
An intriguing recent study also highlighted the requirement for immune activation at the 
very early stages of infection. Using an SIV model, Li et al (2009) showed that the initial 
founder infecting population was small but the innate immune response (plasmacytoid 
DC producing MIP-1(3, MIP-3a, IL-8, RANTES) attracted more target CD4+CCR5+T cells to 
the site of infections which allowed dissemination of the virus to other tissue sites. 
Blockade of the initial innate immune response using glycerol monolaurate, a widely used 
antimicrobial compound, (which specifically inhibits MIP-3a) protected rhesus macaque 
females from infection despite repeated exposure to a high dose of SIV (Li et al., 2009). 
This study further highlights the requirement for immune activation for viral 
dissemination during infection.
The effect of immune activation in HIV-2 infection has been less well studied. Elevated 
levels of soluble p2 microglobulin (P2m, a component of the HLA Class 1 molecule) in HIV- 
2 patients predicted death more accurately than plasma viral load levels (Jaffar, S. et al.,
2005). HIV-2 patients at advanced stages of disease show significantly higher levels of 
immune activation compared to asymptomatic HIV-2 patients. (Michel et al., 2000, 
Leligdowicz et al., 2008). However, comparison of HIV-1 and HIV-2 patients with 
comparable CD4 counts showed similar levels of systemic immune activation (Sousa et 
al., 2002) despite significantly lower viral loads in HIV-2 patients. A separate study
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showed lower levels of activated T cells in female sex workers in Senegal infected with 
HIV-2 compared to HIV-1 subjects but higher than healthy controls (Hanson et al., 2005).
In summary, immune activation plays a pivotal role in progression to AIDS in both HIV-1 
and HIV-2, and lower activation levels in HIV-2 may explain the improved outcome in this 
infection. However, despite the storm of immune activation, an HIV specific response 
does occur in both infections and has been shown to be important in controlling viral 
replication. The understanding of the nature of the specific immune responses and how 
they correlate with protection is still a daunting challenge.
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2.9 Host immunity against HIV-1 and HIV-2
Comparisons of immune responses in HIV-1 and HIV-2 infected individuals have helped 
to identify factors that may contribute to viral replication. Both innate and adaptive 
immune responses have been shown to contribute to HIV control in the respective 
infections.
2.9.1 Innote Immunity
The initial response mediated by the host immune response includes production of IFN-a 
by plasmacytoid dendritic cells (pDC) and proliferation of NK cells, two important 
components of the innate immune system. As discussed earlier, the contribution of pDC 
seems to be more detrimental than helpful to the eventual goal of limiting immune 
activation. In contrast, NK cells are increasingly seen as a key component in recognizing 
and killing infected cells with the help of killer immunoglobulin receptors that recognize 
MHC molecules. The function of NK cells, which act directly on infected cells by inducing 
cytolysis or through the production of chemokine/cytokines, can be severely 
compromised in patients progressing to AIDS. NK cells from HIV-2 infected individuals 
displayed higher functionality in comparison to HIV-1 infected subjects with conserved 
CD4+ T cell counts (Nuvor et al, 2006), but these differences were absent in patients 
progressing to AIDS. This suggests that NK cells contribute to the superior control of viral 
replication observed in HIV-2 infections.
2.9.2. Humoral Immunity
The initial adaptive immune response during acute infection is antibody mediated and 
targeted towards epitopes on the Env, Gag and Pol proteins. Free anti-gp41 IgM 
antibodies are first seen approximately 13 days after the appearance of the virus in the 
periphery and undergo class switching to yield IgG and IgA antibodies (Tomaros et al, 
2008). This is followed in sequential order by antibodies towards gpl20, CD4bs and non­
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neutralizing gp41 envelope membrane proximal external region (MPER). The appearance 
of neutralizing antibodies occurs much later (at approximately 13 weeks post infection) 
and predominantly targets the Env region. (Davis et al., 2009; Moore et al., 2008; Honnen 
et al., 2007; Rong et al., 2007). However, these antibodies are rare in HIV-1 infected 
individuals, with barely 1% of chronically infected patients eliciting broadly neutralizing 
antibodies (Simek et al., 2009; Shen et al., 2009).
Unlike HIV-1, broad neutralizing antibodies are readily detected in HIV-2 patients. Early 
studies showed the presence of broad neutralizing antibodies in sera from HIV-2 infected 
subjects which could neutralize heterologous strains but also some HIV-1 strains (Weiss 
et al., 1988). These results were replicated using sera from HIV-2 patients, which were 
able to neutralize autologous HIV-2 strains but no such neutralization was observed in 
sera from HIV-1 patients (Bjorling et al., 1993). A more recent study showed broader 
neutralizing antibody responses in a large cohort of HIV-2 infected patients compared to 
HIV-1 patients from the same cohort (Rodriguez et al. 2007). While the magnitude was 
lower, the breadth of neutralizing antibody responses was higher in HIV-2 subjects 
compared to HIV-1 infected individuals. The fact that the titer is positively correlated to 
viral load in both infections suggests that neutralizing antibodies elicited are unable to 
efficiently control viral replication, possibly due to escape mutations. However, the 
greater breadth of neutralizing antibody responses in HIV-2 infections suggests that this 
virus may be more susceptible to neutralization.
2.9.3. Cytotoxic CD8 cells
The observation that during the acute phase of HIV-1 infection an increase in cytotoxic 
CD8+ T lymphocytes coincides with a decline in viral load levels in the blood, provided 
evidence that these cells played a pivotal role in viral control. Further proof that CD8+ T
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cells control virus replication in vivo was evident in the SIV model in non-human primates, 
whereby depletion of CD8+ T cells resulted in failure to control the virus both in early 
infection and during the chronic phase (Schmitz et al., 1999). A seminal study by Betts et 
al. (2006) further demonstrated that the quality of the CD8 T cell response was an 
important correlate of protection. Comparison of HIV specific CD8 T cell responses in HIV- 
1 infected progressors and non-progressors showed higher degree of polyfunctionality in 
the latter group (as measured by the simultaneous production of cytokines IL-2, IFN-y, 
MIP-ip, CD107 mobilization and proliferation).
Similar to HIV-1, vigorous anti-Gag CD8+ T cell responses are evident in HIV-2 infected 
individuals (Gotch et al., 1993). Surprisingly, comparison of the magnitude of IFN-y 
release by CD8+ T cells in response to Gag in HIV-1 and HIV-2 patients showed no 
significant differences (Jaye et al., 2004). However, studies comparing T cell receptor 
usage in the two types of infection showed that the plasticity of immune responses was 
superior in HIV-2 judged by a broader polyclonal CD8+ T cell repertoire (Lopes et al, 
2003). This suggested that the ability of HIV-2 to escape the immune response may be 
limited in comparison to HIV-1 as CD8+T cells from HIV-1 infected patients had a much 
narrower TCR usage. In addition, HIV-2 specific CD8+ T cells have been shown to exhibit 
higher polyfunctionality which translated to higher levels of cytokine production on a per 
cell basis (Duvall et al, 2008). The importance of these responses was recently highlighted 
in a study of a community based study HIV-2 infected subjects which showed an inverse 
correlation between T cell IFN-y responses targeted towards epitopes in the Gag protein 
and viral load (Leligdowicz et al., 2007), suggesting that Gag specific cellular immune 
responses accounts for viral control in HIV-2 infection.
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2.9.4. CD4 T-cell response
CD4+ T cell specific responses, especially towards the Gag region, do occur in both HIV-1 
and HIV-2 infections, but the magnitude is lower compared to CD8+ T cells (Duvall et al.,
2007). The quantity and quality of CD4+ T helper responses is strikingly different in HIV-1 
and HIV-2 infections (Duvall et al, 2006). Whereas HIV-2 specific CD4+ T cell activity 
showed preserved polyfunctional responses (IL-2 , IFN-y and proliferation) in patients 
with conserved CD4+T cell counts, such responses were absent in HIV-1 patients.
However, in HIV-1 and HIV-2 infections both CD4+ and CD8+ effector T cell responses 
decline as disease progression occurs. In addition to immune escape mutations, other 
factors that contribute to the diminishing responses include expression of immune 
inhibitory molecules such as cytotoxic T lymphocyte antigen-4 (CTLA-4) and programme 
death-1 (PD-1). The level of expression of these markers on CD4+ and CD8+ T cells 
correlates with disease progression in HIV-1 infections (Kaufmann etal., 2007, Trautmann 
et al 2006, Day et al 2006) but as yet there remain no similar studies in HIV-2 infections.
The host immune response requires a delicate balancing act whereby it must contain 
excessive immune activation while allowing specific anti-HIV responses to successfully 
control viral replication. As the majority of HIV-2 infections progress slowly and immune 
activation is reduced, it is possible that the balance between regulatory and effector 
responses is better compared to HIV-1 infections. A subset of CD4+ T cells that curtail 
exuberant immune activation, termed regulatory T cells (Tregs), maybe key players in 
mediating this balance.
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2.10 T regulatory cells
The concept that the immune system has a dedicated mechanism to prevent 
immunopathology had been suggested as early as 1970 (Gershon and Kondo 1970, 
Gershon 1975). The idea of suppressor cells was temporarily abandoned due to a failure 
to find specific markers that could be used to define these cells. The discovery of CD4+ T 
cells that expressed CD25 (the high affinity chain of the IL-2 receptor) and exhibited 
immunoregulatory properties in mice (Sakaguchi et al., 1995) reignited interest in 
suppressor cells, which were renamed as T regulatory cells. A similar population was soon 
described in humans but unlike mice, only CD4+ T cells that expressed the highest amount 
of CD25 (CD25hi) showed suppressive function ( Baecher- Allan et al. 2001).
A major breakthrough in identifying a specific marker for Tregs was made when the 
forkhead winged helix protein 3 (FoxP3, denoted FOXP3 in humans) was discovered as 
the defective gene in the mouse strain Scurfy (Brunkow et al., 2001). FOXP3 is encoded 
on the X-chromosome and belongs to the forkhead/winged helix family of transcriptional 
regulators which are characterized by the presence of the FKH domain required to bind 
target DNA sequences (reviewed by Ziegeler et al., 2006). FoxP3 expression was shown to 
be restricted to CD4+CD25+ T cells and CD4+CD8 CD25+ thymocytes in normal mice. 
Furthermore, ectopic expression of FoxP3 in CD4+CD25' cells conferred regulatory 
properties to these cells (Fontenot et al., Hori et al., 2003, Khattri et al., 2003). Scurfy 
mice suffer from an aggressive CD4+ and CD8+ T cell-mediated autoimmune disease with 
multi-organ inflammation and die at the age of 3 to 5 weeks. Conversely, depletion of 
FoxP3+ cells in young male mice resulted in a Scurfy like phenotype (Fontenot et al 2003). 
A similar condition is seen in humans, IPEX (immune dysregulation, polyendocrinopathy, 
enteropathy, X-linked syndrome), which results in aggressive autoimmunity and death
within the first two years of life. This has also been linked to mutations in the human 
FOXP3 gene (Gambineri etal., 2003; Bennett etal., 2001).
FOXP3 is essential for the function of Tregs and its expression is required to maintain the 
suppressive phenotype. Loss of FOXP3, or diminished expression of this gene, results in 
acquisition of effector functions characterized by the production of cytokines such as IL-2, 
IFN-y, IL-17 and IL-4 (Wan and Flavell 2007; Williams and Rudensky 2007). In addition, in 
vitro transfection of FOXP3 into human CD4+CD25‘ cells is sufficient to impart suppressive 
function on these cells. Taken together these data show that FOXP3 is essential for the 
Treg phenotype.
2.11 Differentiation of Tregs
Commitment to the Treg lineage has been associated with the induction of FOXP3 in 
thymocytes during their development. Recent data suggests that Treg cell differentiation 
occurs in two steps in the thymus. The first step is dependent on high affinity interactions 
between the T cell receptor (TCR) and its cognate antigen, which results in expression of 
CD25hl FoxP3‘ single positive CD4 thymocytes. The second step requires the presence of 
IL-2, which is required to convert the intermediate population to mature CD25+FoxP3+ 
cells (Lio et al., 2008; Burchill et al., 2008), in a STAT5 dependent manner. In addition to 
TCR engagement and the requirement for IL-2, CD28 co-stimulation seems to play an 
important role in differentiation of thymic derived Tregs as mice deficient in CD28 or 
CD80/CD86 have markedly decreased levels of circulating Tregs ( Salomon et al., 2000; Tai 
et al., 2005).
The generation of Tregs can also occur in the periphery. Both human (Fantini et al., 2004) 
and murine (Betteli et al 2006, Chen et al 2003) naive T cells have been shown to express 
FOXP3 and acquire suppressive activity after TCR stimulation in the presence of TGF-|3
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and IL-2 (Chen et al., 2003). The gut associated lymphoid tissue appears to be a 
preferential site for peripheral induction of FOXP3+ Tregs (Coombes et al., 2007; Mucida 
et al 2005,2007 ; Sun et al 2007) and DCs from the small intestine and mesenteric lymph 
nodes appear to be better inducers of FOXP3 in naive T cells than splenic DCs in the 
presence of exogenous TGF-(3. A different theory suggests that conversion of proliferating 
memory CD4+ T cells to Tregs is a predominant mechanism of induction of Tregs 
(Vukmanovic-Stejic et al., 2006) in response to foreign antigens. Using deuterium 
labeling, the authors highlighted parallel increases in effector and Treg populations that 
utilized the same TCR V(3 families. A more recent study showed that stimulation of human 
PBMCs with bacterial superantigens resulted in a dose dependant induction of FOXP3 in 
CD4+CD25' cells (Taylor et al., 2010).
Until recently, it was not possible to distinguish thymus derived Tregs from peripherally 
induced Tregs. Studies exploring the demethylation status of FOXP3 identified key 
differences in natural and induced Tregs. While natural Tregs showed complete 
demethylation of a specific locus named as Treg cell specific demethylated region (TSDR) 
found on exon 1 of the FOXP3 gene, this locus was only partially demethylated in induced 
Tregs (Floess et al., 2007; Huehn et al., 2009). Furthermore, thymically derived Tregs 
display high expression of the transcription factor Helios which is absent in peripherally 
induced Tregs (Thornton et al., 2010).
2.12 Treg phenotype
The phenotype of mature Tregs remains a contentious issue. Tregs constitutively express 
high levels of FOXP3 and these cells display low or negative surface expression of IL-7Ra 
(Seddiki et al., 2006). Although CD25 was the initial marker used to define Tregs, it has 
become apparent that FOXP3 expression does occur in CD25' cells as well (Finney et al.,
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2010), leading to suggestion that CD25 maybe a marker of activation on Tregs (Finney et 
al 2009). Tregs also express high levels of cytotoxic T lymphocyte antigen 4 (CTLA4), 
CD39, CD73, though none of these markers are exclusive to Treg cells. To date the most 
accurate description of Tregs remains CD4+CD127lo/"FOXP3+ and is now widely used to 
enumerate these cells.
2.13 Mechanism of Treg action
Tregs utilize multiple mechanisms to suppress effector responses such as the secretion of 
IL-2, IFN-y and proliferation. The intriguing question which was posed early, but as yet not 
conclusively answered, was whether Tregs require direct contact with target cells to 
mediate their suppressive function. While most of the in vitro data suggested that the 
predominant mechanism of suppression was contact-dependent, in vivo results from 
mouse models indicate that the mode of suppression could be cytokine mediated. 
However, such data is difficult to obtain in human studies and has been complicated by 
the failure to identify a soluble mediator emanating from Tregs.
Evidence for the requirement for direct cell contact by Tregs to mediate their suppressive 
capacity has come from Transwell experiments. Physical separation of Tregs and effector 
cells results in enhanced proliferative and cytokine responses in the latter subset after 
TCR stimulation, suggesting that cell contact is required by Tregs to exert control over 
effector functions. Do Tregs exert their suppressive activity by acting directly on effector 
cells or on antigen presenting cells? In vivo imaging experiments in mice have highlighted 
the fact that Tregs swarm around DCs and hinder prolonged contact between DC's and 
naive T cells, suggesting abortive priming of effector cells (Tang et al 2006; Tadokoro et al
2006). The precise ligands that mediate Treg-DC contact are still not clear but it appears 
that the co-stimulatory molecule CTLA-4 is a major contributor to Treg function. CTLA-4, a
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member of the CD28 superfamily, is a co-stimulatory molecule which is constitutively 
expressed on Tregs. In the absence of functional CTLA-4 or its blockade using antibodies 
resulted in reduced suppression of effector T cells by DCs (Oderup et al., 2006; Serra et 
al., 2003). CTLA-4 ligation of co-stimulatory molecules CD80 or CD86 also resulted in 
production of indolemine 2,3, dioxyegenase (IDO), which catabolises tryptophan to yield 
proapoptotic metabolites that are potent suppressors of effector T cells (Fallarino et al 
2003 ; Mellor et al 2004). Other studies have shown that Tregs can down regulate CD80 
and CD86 expression In vitro on DC's which would reduce their ability to prime effector T 
cells (Cedeborn et al., 2000). However, a more recent study showed that Tregs were 
more mobile than effector T cells after TCR stimulation and better at aggregating around 
DCs, which was independent of CTLA-4 but required the presence of Leukocyte function- 
associated antigen -1 (LFA-1). CTLA-4 was however required for downregulation of CD80 
and CD86 on DCs in agreement with other studies. (Onishi et al 2008). Several other 
studies have suggested that Treg mediate modulation of the maturation and function of 
DCs (Kryczek e ta !2006; Lewkowich etal., 2005., Houot etal., 2006., Misra eta!., 2004)
More recently another mechanism of suppression has been described which is 
dependent on the activities of two ectoenzymes CD39 and CD73 (Deaglio et al., 2007). 
The expression of both these enzymes has been shown to be upregulated on Tregs. The 
concordant expression of these two enzymes results in the pericellular generation of 
adenosine, which is a potent suppressor of proliferation of effector T cells, as well as 
encouraging the induction of adaptive Tregs. Adenosine has a half-life of 10 seconds 
which suggests that there needs to be close proximity between Tregs and effector cells 
for the effects of this molecule to be maximized. The generation and subsequent transfer 
of cyclic AMP from Tregs to effector cells via gap junctions has also been highlighted as a
potential mechanism of Treg suppression (Bopp et al., 2007). These mechanisms need 
further investigation and could yield potential mechanisms to that can be used to 
modulate Treg activity.
2.14 Tregs and infectious diseases
The outcome of an infection is usually dictated by action of the host immune response. 
While some pathogens are cleared, others persist despite the induction of a robust 
immune response. The pioneering study of the role of Tregs in infectious diseases was 
one that showed Treg abrogate Thl responses required for clearance of Leishmania from 
sites of primary infection in a mouse model (Belkaid et al., 2002). A small number of 
parasites persist in tissue lesions, which was found to be dependent on IL-10 emanating 
from CD4+CD25+ Tregs. Parasite persistence was required for maintenance of protective 
immunity but at the same time T cell mediated immunopathology needs to be avoided. 
The realization that Tregs are important modulators of the host immune response during 
infection led to a whole plethora of studies investigating their role in a variety of 
infectious diseases.
In malaria, Tregs induced after sporozoite challenge correlated with pro-inflammatory 
responses and higher parasite loads (Walther et al, 2005). In a follow-up to this study, 
Finney and colleagues demonstrated that Tregs levels were higher among individuals 
living in a rural village in Gambia with high malaria transmission compared to an urban 
area with negligible malaria transmission (Finney et al., 2009). This study suggested that 
Tregs were essential in maintaining immune homeostasis in environments with frequent 
persistent antigenic exposure. Also, Treg activity during acute Plasmodium falciparum 
malaria dictated subsequent malaria specific memory responses in children (Walther et 
al., 2009). Similarly, the levels of Tregs have been linked to clinical outcome in West Nile
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virus infections, which leads to symptomatic disease in approximately 20% of infected 
subjects: a longitudinal study of Tregs in infected patients showed that asymptomatic 
patients had significantly lower levels of Tregs compared to patients who developed 
clinical symptoms of disease (Lanteri et al., 2009). Collectively these studies suggest that 
induction of Tregs early after an infection has a bearing on the subsequent clinical 
outcome of acute infections.
During most chronic infections Tregs levels are elevated and accumulate at the sites of 
infection. During Mtb infections, Treg cell numbers are increased both in the blood and 
sites of infection and the frequency of FOXP3+ cells inversely correlates with Mtb- specific 
immunity (Chen et al., 2007, Qin et al., 2008, Roberts et al., 2007, Hougardy et al., 2007). 
Using a mouse model of Mtb infection, a recent study suggested that increased levels of 
Mtb specific Tregs may be detrimental and contribute to delayed priming and trafficking 
of effector cells to the site of infection, thus allowing the bacteria to persist (Shafiani et 
al., 2010). Similarly, FOXP3+ cells accumulate in the conjunctiva of patients infected with 
Chlamydia trachomatis (Faal et al., 2006). Chronic HBV infection is characterized by an 
elevated frequency of FOXP3+ cells in the periphery as well as in the liver and correlates 
with viral load (Peng et al., 2008, Stoop et al., 2007). Expansion of HBV specific Tregs 
have been associated with liver pathology evident during infection (Xu et al., 2006). In 
HCV infections Treg levels are raised in chronic infection and accumulate in the liver 
(Smyk-Pearson et al., 2008; Ward et al., 2007). Furthermore, these cells were shown to 
exhibit high suppressive ability as depletion of Tregs in vitro from chronically infected 
HCV patients' results in increased CD8+T cell responses.
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These studies highlight the significant role played by Tregs in the pathogenesis of various 
infectious diseases and may in the future serve as targets for intervention to treat these 
diseases.
2.15 Tregs in HIV: Friend or foe?
The role of Tregs in HIV infection continues to generate strong interest and controversy 
due to conflicting data about their potential role in disease pathogenesis. The chronic 
stage of HIV-1 infection is characterized by the progressive loss of CD4+ T cells 
accompanied by persistently high levels of immune activation and immune dysfunction. 
Tregs act to curtail excessive immune activation and so in the context of HIV-1, the 
debate as to whether Tregs help or hinder control of HIV infections rages.
Many of the early studies investigating the role of these cells in HIV infection focused on 
whether Tregs were responsible for diminution of cell mediated HIV-1 specific responses. 
Since conjugated antibodies towards FOXP3 were not available, most of these studies 
used CD25 expression on CD4+ T cells or mRNA levels of FOXP3 to define Tregs. In vitro 
depletion of CD25+ cells from HIV-1 positive individuals resulted in increased anti-HIV 
specific immune responses (Kinter et al., 2004, Andersson et al., 2005; Weiss et al., 2004; 
Aandahl et al., 2004), suggesting that Tregs played a detrimental role in HIV-1 disease by 
reducing HIV-specific immune responses. In contrast, other reports suggested that failure 
to control the excessive levels of immune activation seen in HIV-1 infection was a direct 
result of reduced Treg frequencies or impaired suppressive ability of these cells (Oswald- 
Richter et al., 2004; Apoil et al., 2005). However, these early studies were clouded by 
differences in the phenotype used to define Tregs, differing methodologies used to 
measure Tregs and sampling of HIV-1 patients at different disease stages.
More recent studies, which included FOXP3 as a signature for Tregs, have shown that the 
frequencies of Tregs (expressed as a percentage of total CD4+T cells) are increased in the 
periphery (Tsunemi et al, 2005; Montes et al., 2006, Rallon et al. 2009) and in mucosal 
tissues (Epple et al., 2006) during the chronic stage of HIV-1 infection and inhibited HIV 
specific immune responses. Moreover, other studies showed that Tregs accumulation in 
lymphoid tissue correlated with viral replication in HIV-1 infection and with progression 
to AIDS (Nilsson et al, 2006). Collectively these studies suggest that Tregs inhibit HIV 
specific responses and allow viral persistence.
HIV replication causes an incremental increase in immune activation through direct or 
indirect effects and Treg mediated control of such activation would be required. 
However, Treg activity also results in diminution of HIV specific immune responses which 
may assist viral persistence. Furthermore, Tregs are targets of HIV infection and can be 
induced in response to increased levels of activation. Defining the precise role of Tregs in 
the pathogenesis of HIV-2 infections would certainly assist in understanding the factors 
that contribute to successful viral control.
2.16 Tregs in SIV infection
The study of Tregs in pathogenic and non-pathogenic models of SIV infection has yielded 
important clues about the role these cells play in controlling generalized immune 
activation and SIV specific immune responses. The distinguishing feature of non- 
pathogenic SIV infection is the lack of persistent immune activation even though high 
levels of viral replication occurs in both models (Silvestri et al., 2003). A strong anti­
inflammatory profile, which comprised of an early up regulation of TFG-(3 and IL-10 in 
African green monkeys, coincided with an increase in Tregs and was associated with 
protection from AIDS (Kornfeld et al., 2005). Furthermore, depletion of Tregs was
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observed in the GALT of SIV infected macaques (Chase et al, 2007) which correlated with 
loss of suppressive activity of CD4+ T cell from these animals. The dynamics of Tregs in 
acute SIV infections have shown its early upregulation in both pathogenic and non- 
pathogenic models but these cells are transiently lost in the pathogenic model. Another 
important subset of CD4+ T cells capable of producing IL-17 (aptly referred to as Thl7  
cells) were also maintained in non-pathogenic SIV infection, and the ratio of Thl7/FoxP3 
positive cells was inversely proportional to CD8+ T cell activation levels in blood, lymph 
nodes and mucosal tissue (Favre et al., 2009). A more recent study linked the suppressive 
capacity of Tregs to maintenance of high CD4 T cell counts in experimentally infected 
Macaques (Karlsson et al., 2010). Therefore, in the context of non pathogenic SIV 
infection, Tregs appear to play a beneficial role during the acute stage of infection by 
controlling excessive immune activation levels which helps prevent progression to AIDS.
As yet there are few comparative studies of Treg frequencies or function in HIV-2
---------------- infections. HIV-1 and HIV-2 represent infections with similar viruses but distinctly
different outcomes. We present a comparative analysis of the phenotype, frequency and 
function of Tregs in HIV-1 and HIV-2 infections in a West African Clinical cohort.
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2.17 Rationale of the study
Studies of the role of Tregs in progressive versus non-progressive disease in humans are 
scarce. Although, studies in SIV infection models provide useful insight into pathogenesis 
of AIDS like illness, there are substantial differences with the HIV infection model. HIV-2 
remains the only other lentivirus known to infect humans and can cause AIDS. The 
majority of HIV-2 infected patients behave as long term non-progressors characterized by 
well functioning immune responses accompanied by lower levels of systemic immune 
activation. We hypothesized that the balance between effector and regulatory responses 
is better preserved in HIV-2 compared to HIV-1 infections that explains the improved 
prognosis in HIV-2.
The objectives of the study were:
________________1) Enumerate Treg frequencies in chronic HIV-1 and HIV-2 infected individuals
(progressors and non-progressors)
2) Relate Treg frequencies to immune activation, viral load levels and CD4+ T cells 
counts in HIV-1 and HIV-2
3) Determine the balance between effector and regulatory responses during 
asymptomatic HIV-1 and HIV-2 infections
4) Explore the effects of HAART on Treg frequencies and explore their potential 
involvement in the development of immune reconstitution syndrome
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Chapter 3: General Methods
3.1 Patients
The studies described in the subsequent chapters of this thesis were conducted at the 
MRC Laboratories in The Gambia. The Gambia is located on the West Coast of Africa and 
has one of the smallest land masses on continental Africa. The Gambia has a population 
of 1.6 million and the predominant ethnic tribes are Mandinka (42%), Fula (18%), Wolof 
(16%) and Jola (10%). The other ethnic groups include the Manjago, Bambara and Krio 
Aku Marabout. The majority of Gambians practise Islam (90%) as their religion while 
Christianity and traditional religions are also practised by approximately 10% of the 
population.
The MRC Laboratories in The Gambia has been active since its inception in 1947. The 
MRC runs a specialized Genito-Urinary Medicine (GUM) clinic which acts as a referral 
centre for HIV infected patients. Patients visiting this clinic were enrolled into the Fajara 
cohort after giving informed consent. These patients typically visited the clinic 3-6 times a 
year and provided a sample of blood for viral load and CD4 monitoring. At the end of 
2008, there were 3995 patients registered at the clinic of which approximately 2200 
patients were known to be alive. HIV-2 infected patients constituted twenty seven 
percent of these patients with a further seven percent were dually infected with both 
HIV-1 and HIV-2.
HIV-1 and HIV-2 patients enrolled into the MRC Fajara cohort were consented and 
enrolled in to the study. A total of eighty three HIV-1 and 72 HIV-2 patients who were 
antiretroviral therapy naive, >18 years of age and did not present with any concurrent 
infections such as tuberculosis and malaria were recruited for the studies. Any patients 
that were dually infected with both HIV-1 and HIV-2 were excluded from the study.
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Another eighty patients were recruited for the IRIS Study at the time they were to 
commence antiretroviral therapy and sampled at time 0,1/2,3 and 6 months after 
commencement of therapy. These patients received counseling from experienced staff at 
the MRC before commencement of therapy and were encouraged to visit the GUM clinic 
if they experienced any adverse events. Viral load and CD4 T cell counts were measured 
for all patients for each individual visit to the GUM clinic.
These studies were approved by the Gambia Government/MRC Ethical Committee (see 
Appendix).
3.2 HIV Diagnosis and viral load testing
HIV screening was performed using the Murex ICE HIV-1.2.0 capture enzyme 
immunoassay (Murex Diagnostics).Patient samples that displayed a positive result were 
further tested using a Hexagon (Human GmbH, Germany) line assay which measures 
antibodies against viral proteins gp41, p24 and gp36 in plasma to discriminate between 
HIV-1 and HIV-2 patients. In the event of an indiscriminate result, plasma samples were—  
further tested using the Pepti-Lav kit (Sanofi Diagnostics, Pastuer).
Plasma viral load was quantified by an in-house reverse transcriptase assay as previously 
described (Berry et al., 1998; Alabi et al., 2007). Undetectable viral load was assigned an 
arbitrary value of 100 copies/ml and the upper detection limit of the assay was 1000000 
copies/ml.
3.3 CD4T cell counts
Enumeration of CD4 levels (CD4% of total CD3 T cells) was done using BD MultiTest 
reagents and Multiset software (BD Biosciences, USA). Briefly, 50pl of Whole blood was 
incubated with lOul of the Multitest (BD Biosciences, UK) antibody (anti-CD4, anti-CD8, 
anti-CD3, and anti-CD45) cocktail. The cells were then lysed with IX  FACS Lysis solution
(BD Biosciences, UK) and acquired on a 4-color FACS Calibur using the Multiset software.
Whole blood counts and lymphocyte percent were measured using a Medonic 
haemoanalyzer (Clinical Diagnostic Solutions Inc, USA), which was used to calculate the 
absolute numbers of CD4+, CD8+ and CD3+ T cells per pi of whole blood.
3.4 Whole Blood FACS Staining for cell surface and intracellular markers
Whole blood FACS staining was performed on freshly isolated venous blood and 150pl
was used per tube. This amount of blood was also used to stain for the individual
conjugated CD8 antibodies that were required for adjusting compensation values on the
flow cytometers.
A cocktail of surface antibodies was prepared (CD4-PerCP, CD25-FITC, and CD127-PE) and 
added directly to 150 pi of whole blood. After a 30 min incubation at room temperature 
in the dark, the cells were washed with FACS Buffer (PBS containing 2% BSA, 0.2 % EDTA) 
to remove any unbound antibody. The cells were then fixed and permeabilised using
500pl of Fix:Perm buffer (Ebiosciences, San Diego, USA) and incubated for 30min at 4°G----------
to facilitate detection of intracellular markers. The cells were then washed with FACS 
Buffer and then with Perm Buffer (Ebiosciences, San Diego), and resuspended in 50 pi of 
Perm Buffer containing 2% Rat Serum. After 15 min of incubation at 4°C conjugated 
antibodies for intracellular marker (FOXP3-APC) were added. The cells were then 
incubated for 30min at 4°C, washed with Perm Buffer and resuspended in 200pl of PBS.
The cells were collected on a four-color FACSCalibur (BD) instrument. Data was analyzed 
using FlowJo software (TreeStar Inc., Ashland, OR, USA).
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3.5 (32-microglobulin measurement
140pl of Plasma was used to determine the levels of soluble |32- microglobulin ((32m), 
which is a component of the major histocompatibility complex (MHC) class 1 found on all 
nucleated cells Soluble levels of (32m have been shown to be a good marker of immune 
activation in HIV infected patients and reliably predict progression to disease (Jaffar et ol
2005).
Undiluted plasma from HIV-1 and HIV-2 patients was used to measure (32m levels using 
the automated AxSYM (3-2 microglobulin assay (Abbot, USA). This assay relies on anti (32m 
antibody coated microparticles that bind soluble (32m in the plasma sample forming an 
antigen-antibody complex. Anti (32m: Alkaline Phosphatase conjugate is first added and 
binds to the antigen-antibody complex. After washing any unbound conjugate the 
substrate 4-Methylumbelliferyl Phosphate is then added and the resulting fluorescent 
product is measured against a standard curve generated from known standards provided 
by the manufacturer. The lower limit of detection was 200pg/L, while the upper limit of 
detection was 4000 pg/L. Samples, in which (32m levels were above the upper limit, were 
retested using the automated dilution protocol (1 in 20 dilution).
3.6 Isolation of PBMC
Up to 15ml of venous blood were collected in a heparinised tube. The samples were
centrifuged for 5 minutes at 400g and the plasma was collected and stored at -70 QC. The
remaining sample was diluted 1:1 in RPMI and carefully layered onto a 4 ml of Nycoprep
density gradient and centrifuged for 30 minutes at 400g at room temperature, centrifuge
brake turned off. PBMC were transferred into a fresh tube, washed twice in RPMI 1640
(10 minutes, 400g), and resuspended at a concentration of 1x10s cells/ml in complete
culture medium (RPMI 1640, 10% human serum (Sigma), lOOU/ml penicillin (Sigma),
lOOpg/ml streptomycin (Sigma), and 2mM L-glutamine (GIBCO/lnvitrogen, Paisley, UK).
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The cells were rested for two hours at 37^C after which they were used for overnight 
stimulations and measurement of intracellular cytokine staining and activated T cells as 
described below.
3.7 Intracellular cytokine staining for production of HIV-specific CD4 and CD8 T cells 
The levels of HIV-1 and HIV-2 specific CD4 and CD8 T cells were evaluated using overnight
stimulation followed by intracellular cytokine staining. Overlapping Gag HIV-1 peptides
based on consensus sequences of Clade A (15 mers overlapping by 10) were obtained
from the National Institute of Health AIDS Research and Reference Reagent program.
Peptides were dissolved in DMSO (Sigma-Aldrich) at lOOmg/ml and diluted with RPMI to
a final concentration of 20mg/ml before being individually filtered. The peptides were
pooled, and aliquots stored at -70gC. HIV-2 Gag peptide pools (18 mers overlapping by
10) based on the consensus sequence from Clade A were kindly donated by Dr
Aleksandra Leligdowicz (Leligdowicz et al 2007).
lxlO^cells were stimulated with CD28/CD49d alone (negative control), Gag peptide pools 
(2pg/ml) or SEB (2pg/ml, positive control). The CD107a-PE antibody (a marker of cellular 
degranulation) was added at time 0. After 3 hours, lOpg/ml of protein transport inhibitor, 
brefeldin A (BD Biosciences, USA), was added and cells were incubated overnight. At the 
end of the incubation, cells were washed and permeabilised for 20 minutes at 4°C with 
the Fix/ Perm Buffer diluted in 1:4 with diluents provided by the manufacturer 
(Ebiosciences, US). Cells were then washed and incubated with 2% rat serum for 15 mins 
to reduce non-specific binding of antibodies. Cells were then simultaneously stained with 
six antibodies using the following panels: IFN-y- FITC, CD4 PerCP, CD8 PE-Cy7, IL-2 APC 
and FOXP3-PB. All conjugated antibodies were obtained from Ebiosciences, while the 
PerCP conjugated antibodies were purchased from BD Biosciences. Cells were acquired
on the Cyan flow cytometer which was fitted with three lasers (488nM (Blue), 405nM 
(Violet) and 635nM (Red)). Unlike the FACSCalibur which is only fitted with two laser and 
can measure only four parameters, the Cyan machine can simultaneously measure 
emissions from up to nine fluorochromes. A minimum of 300,000 events were collected 
for each sample.
3.8 Measurement of T cell activation marker expression
Expression of the CD38 (cyclic ADP ribose hydrolase) on T cells was shown to be an 
accurate marker on activation which correlated with progression to AIDS (Giorgi et al., 
1993 & 1999). In addition, HLA-DR, an MHC Class II molecule measured in conjunction 
with CD38 was shown to be raised on CD8 T cells in HIV-1 infections compared to healthy 
controls (Kestens et. al, 1992). To determine the levels of immune activation in the T cell 
compartment in HIV-1 and HIV-2 patients freshly isolated PBMC (1 X 106 cells) were used 
for determination of T cell surface activation marker expression using anti-HLA-DR PerCP 
(BD Biosciences, USA), CD38 APC, CD4 PerCP, CD8 FITC, CD127 PE and FOXP3 PB titrated 
monoclonal antibodies (Ebiosciences, USA). Samples were analysed using a 9-Colour Cyan 
(Becton Dickinson, USA) and data was analyzed using FlowJo (Tree Star).
3.9 Depletion of Tregs from PBMCs using positive selection of CD25+ cells
CD25+ cells were selectively removed using magnetic bead cell sorting (MACS) from
Miltenyi. Freshly isolated PBMC (minimum of 6 million cells) were split into two equal
aliquots. One aliquot was labeled as the undepleted fraction and rested at 37QC until
required. PBMC from the second aliquot were washed and resuspended in FACS Buffer
(Phosphate Buffered Saline (Sigma, UK) containing 2% BSA and 0.5mM EDTA). CD25+
beads were added at a ratio of 5:1 to cells and incubated for 20 mins at 4QC. Cells were
then pelleted (3000g, 5 mins) and resuspended in 2 ml of FACS Buffer. The cells were
then put through a MACS column attached to a magnet. The column was washed three
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times with FACS buffer and the flow-through was collected as the CD25' fraction. CD25+ 
cells were obtained by adding 1 ml of FACS Buffer and flushing the column using the 
plunger provided. The cells in the CD25' and CD25+ fraction were resuspended in 
complete media and counted before they were rested at 379C. An aliquot of the CD25+ 
and CD25' fractions were stained with CD25 FITC, CD127 PE, CD4 PerCP and FOXP3 to 
determine purity of the samples.
3.10 RNA Extraction
RNA was extracted from 2.5 ml of whole blood preserved in PAXGene tubes (Qiagen, UK) 
using the PAX gene Blood RNA Kit (Qiagen/BD, UK) as recommended by the 
manufacturer. The PAXGene tubes containing the whole blood samples were incubated 
at room temperature overnight to ensure lysis of cells and subsequently stored at -709C. 
To extract RNA, PAXGene tubes were thawed and nucleic acids were pelleted by 
centrifugation (3000g, lOmins) and resuspended in buffers supplied by the manufacturer 
together with Proteinase K. The cell lysate was transferred to PAXgene Shredder spin 
column, centrifuged and supernatant collected in a fresh microcentrifuge tube. RNA was 
purified by passing it on to the PAXgene RNA spin column, then washed and treated with 
DNase. RNA was eluted in a final volume of 80pl and stored at -70°C. lp l of each sample 
was used to quantify RNA levels using the Nanodrop spectrophotometer (Thermo 
Scientific, US). All RNA samples were stored at -709C.
3.11 Real Time PCR
Real time PCR is a technique that allows for the simultaneous amplification and 
quantification of a region of DNA. Coupled with reverse transcription which converts RNA 
to DNA, this method provides a useful method to measure the relative expression of a 
particular gene. The expression of the gene of interest has to be normalized against the 
expression of constitutively expressed genes (housekeeping genes).
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To measure FOXP3 expression in HIV-1 and HIV-2 infected patients an aliquot of blood 
was stored in a collection tube containing RNA stabilizing agents (PAXgeneTM Blood RNA 
System, Pre-AnalytiX)) and stored at -70gC. RNA was isolated as described above. cDNA 
was synthesized using One step RT Reagents (Qiagen, UK) following the manufacturer's 
instructions. The FOXP3 and Beta-glucuronidase (GUSB) assays were performed using the 
QuantiTectTM SYBR® Green PCR kit while the HUPO Probe assay was performed using the 
QuantiTectTM Probe PCR kit (Qiagen). Primers used for each assay are listed in Table 3.1.
Primer Sequence
Annealing
(9C)
Number of 
Cycles
FoxP3 F 5' ACCTGGAAGAACGCCATC 3’
58 40FoxP3 R 5' TGTTCGTCCATCCTCCTTTC 3'
HuPO-F 5' GCTTCCTGGAGGGTGTCC 3’
_____ 56_____ _____ 40______
HuPO-R 5' GGACTCGTTTGTACCCGTTG 3’
HuPO
probe
5'FAM-TGCCAGTGTCTGTCTGCAGATTGG- 
TAMRA 3 '_____________________________
GUSB-F 5' AAA CGA TTG CAG GGT TTC AC 3'
55 40GUSB-R 5' CTC TCG TCG GTG ACT GTT CA 3'
Table 3.1: Primers pairs and conditions for real time PCR assays
For each individual assay a standard curve (range 106- 101 copies) was generated using 
gel purified PCR products. Each individual sample and standards were run in duplicate 
and the results were displayed as mean copy numbers. All assays were performed on the 
DNA Engine Opticon® Continuous Fluorescence Detection System (MJ Research, 
Waltham, MA, USA), and analyzed using Opticon Monitor 2TM analysis software.
66
3.12 Quantitation of cytokines in Human Plasma
Multiplex quantification of cytokine concentrations in plasma samples was performed 
using the Bio-plex® 200 system (Bio-Rad Laboratories). This commercially available assay 
allows for the simultaneous measurement of cytokine levels in plasma samples, which 
rely on antibody conjugated beads. Levels of IL-2, IL-6, IL-10, IL-17, IL-12, IFN-y, MIP-ip  
and TNF-a were determined using the x-PlexTM assays according to the manufacturer's 
instructions (Bio-Rad Laboratories). Data analysis was performed using the Bio-Plex® 
Manager software (Bio-Rad Laboratories). The lower limit of cytokine detection was 
defined as the concentration corresponding to a fluorescence value 3SD above the mean 
background fluorescence in control wells (IL-2 3.99 pg/ml, IL-10 3.56 pg/ml, IL-17 43.22 
pg/ml, IL-12 3.99 pg/ml, IFN-y 7.58 pg/ml and TNF- a 8.24 pg/ml); values above this 
threshold were designated as responders, values below were arbitrarily set to the 
threshold value.
3.13 Statistics
Data was analyzed using Stata software Version 9.2. Kruskal-Wallis test was used to 
analyze the medians of non-normally distributed variables between groups. For linear 
regression and calculation of Pearson's correlation coefficients variables were log 
transformed to satisfy the condition of normal distribution when using these statistical 
tests. The non-parametric Spearmans' test was used to assess correlation on non- 
normally distributed data. Statistical significance was defined as p<0.05.
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Chapter 4: Phenotype and quantification of 
T regulatory cells in HIV infected patients 
and healthy controls
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4.1 Introduction
The immune system has multiple checks to ensure a controlled response in order to avoid 
host damage. The idea that the immune system possesses an endogenous subset of T 
cells that are professional suppressors was suggested in the 1970s (Gershon and Kondo, 
1970) but interest in this field waned due to a failure to identify a cellular marker that 
defined these cells. The finding that CD4+ T cells expressing the a-chain of the IL-2 
receptor (CD25) possessed suppressor activity re-ignited interest in the field and led to 
the rebirth of interest in suppressor T cells renamed as T regulatory cells (Tregs), 
(Sakaguchi et al., 1995). This was given more impetus by the finding that expression of 
the transcription factor forkhead box protein P3 (FOXP3) was essential for suppression, 
thus providing an additional and more precise marker to define these cells (Fontenot et 
al., 2003, Hori et al., 2003, Khattri et al., 2003). However since FOXP3 is an intracellular 
marker which required fixing and permeabilising cells, it was necessary to identify other
----------------------cellular markers to allow functional studies of these cells. It was observed that the IL-7
receptor was down regulated on CD4+FOXP3+ cells and showed an inverse correlation 
with expression levels of FOXP3 (Liu et al., 2006; Seddiki et al., 2006) and this provided an 
additional useful marker.
The caveat for the use of markers attributed to Tregs (CD25, HLA-DR, low CD127) has 
been that they are also present on activated T cells. During HIV infection, the immune 
system is chronically activated which results in an increase in activation markers such as 
CD25, HLA-DR and down regulation of CD127, all of which can be expressed on 
CD4+FOXP3+ cells. Therefore identifying the optimal signature to define Tregs in HIV 
studies has been a challenge.
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More recent studies have indicated that CD4+FOXP3+ cells represent a heterogeneous 
population of naive and memory Tregs that are equally suppressive but display different 
homing and functional markers such as CTLA-4(Cytotoxic T-Lymphocyte Antigen-4, 
CD152) and CD39(Ectonucleosidetriphosphate diphosphohydrolase l)(Deaglio et al., 
2007, Miyara et al., 2009). CD39 hydrolyzes ATP/UDP and ADP/UDP to generate 
nucleoside monophosphates, which can be degraded further to nucleosides such as 
adenosine. The generation of adenosine by CD39 enzymatic activity has been 
demonstrated to suppress proliferative responses (Ohta et al., 2001). CTLA-4 is another 
negative regulator of T cell function and competes with CD28 for ligation with CD80 and 
CD86 on antigen presenting cells. CTLA-4 ligation results in decreased IL-2 production, 
inhibition of cell cycle progression and modulation of TCR signaling (reviewed by 
Bluestone et al., 2008).
Memory Tregs (defined by the expression of CD45RO) are the predominant subset of 
Tregs; and express CTLA-4, CD25, GITR and CD95 in aduIts (Sakaguchi e ta  17,2004). These 
cells preferentially home to tissue as they express high levels of the chemokine receptor 
CCR4 and are very prone to apoptosis induced cell death (Fritzsching et al., 2005a). In 
contrast naive Tregs (CD45RA+ FOXP3+) cells express CCR7 and home to the lymph nodes 
and express low levels of CD25 and CTLA-4 as well as FOXP3 (Fritzsching et al., 2005b). 
The majority of these cells also express CD31 (Platelet endothelial cell adhesion molecule 
(PECAM-1)) which indicates that they are recent thymic emigrants (Booth et al., 2010). 
Interestingly, naive Tregs are relatively resistant to CD95L mediated apoptosis compared 
to memory Tregs, but upon stimulation can rapidly convert to memory Tregs (Fritzching 
et al., 2006).
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Faced with such diversity in classification, it is therefore not surprising that the role of 
Tregs in HIV remains a contentious subject. Many of the early studies exploring Tregs in 
HIV infection were marred by inconsistencies relating to the phenotype used to 
enumerate these cells. More specifically, the use of CD4+CD25+ before conjugated 
antibodies to FOXP3 became available, has resulted in erroneously defining activated 
cells as Tregs. Other studies utilized CD4+CD25hl to define Tregs (Kinter et ol., 2004), and 
while this population has been shown to contain more FOXP3+ cells, it remains an 
imprecise definition. More recent studies have identified Tregs as CD4+FOXP3+ 
CD4+FOXP3+CD25+, CD4+CD127lo/'FOXP3+ or CD4+CD25+CD127|0 (Krathwohl et ol 2006; 
Epple et ol.2006; Kinter et. al 2007;Lim et ol.,2007; Seddiki et ol; 2009,).
Before the availability of conjugated monoclonal antibodies against FOXP3, many studies 
using HIV subjects measured the messenger RNA (transcript) levels of FOXP3 as a 
surrogate marker for frequency of Tregs (Oswald-Richter et ol., 2004; Kinter et ol., 2004;
----------------------Weiss et o/rr Eggena et ol., 2005; Apoil et o/., 2005). However, as yet there remain nor
reports that have evaluated whether FOXP3 transcript levels correlate with frequencies 
of CD4+FOXP3+ cells measured using flow cytometry.
In this chapter the optimal combination of markers to measure Tregs using flow 
cytometry was explored. The proportion of naive and memory Tregs of the total 
CD4+FOXP3+ in HIV-1, HIV-2 and healthy controls was also determined. The levels of 
CD4+FOXP3+ cells, as measured by flow cytometry, was also compared to quantitative 
real-time PCR measurement of FOXP3 transcript levels.
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4.2 Materials and methods
4.2.1 Subjects
Whole blood was collected from HIV-1, HIV-2 infected subjects and healthy controls 
individuals attending the GUM Clinic at the MRC Laboratories in The Gambia as described 
in Chapter 3 (Materials and methods).
4.2.2 Phenotyping and Quantification of Tregs using flow cytometry
To determine the appropriate surface and intracellular markers to identify Tregs, aliquots
of whole blood were stained with the following panels of antibodies:
1) CD25-FITC, CD127-PE, CD4-PerCP, FOXP3-APC
2) CD39-FITC, CD27-PE, CD4-PE-Cy7, CD45-RO PE-Cy5, CD28-APC, FOXP3-PB
3) CD39-FITC, CTLA-4 PE, CD4 PE-Cy7, HLA-DR PerCP, CD25-APC, FOXP3-PB
With each run an isotype control for FITC was included in order to define the cut-off for 
CD39 and CD25 positive staining. All samples were acquired on a 9-color Cyan machine 
(Beckman Coulter, USA)_and_a minimum of 100,000 events were collected in the CD4 
gate. The FCS files were analyzed using FlowJo software version 7.2.5
4.2.3 Quantitative Real-time PCR
RNA was extracted from whole blood collected from study samples in PAXGene tubes 
(Qiagen, UK) according to the manufacturer's recommendations. An aliquot of RNA was 
reverse transcribed to copy DNA (cDNA) and the levels of FOXP3 mRNA were measured 
as described in the Materials and methods chapter (Chapter 3).
4.2.3 Statistics
Data were analyzed using Stata software Version ll(Stata Corp, USA) and data graphs 
were prepared using Prism (v5). Correlations were tested using Spearman's rank 
correlation co-efficient for non-normally distributed data. Statistical test results were 
considered significant if p<0.05.
4.3 Results
4.3.1 Definition of Tregs in HIV infections using flow cytometry:
The combination of cell surface and intracellular markers used to quantitate Tregs in HIV 
studies has varied between studies. FOXP3 is required for the maintenance and function 
of Tregs (Fontenot et ol., 2003). Thus we sought to optimize Treg identification by using a 
combination of appropriate cell surface markers in conjunction with FOXP3 in direct 
whole blood staining, rather than using more purified PBMC. Such a method required less 
blood (see fig 4.1).
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Figure 4.1: Gating strategy to enumerate Tregs in whole blood samples: A) Lymphocyte 
gate (Forward scatter versus Side scatter) B) CD4 gate (CD4 versus Forward Scatter) C) 
CD4 versus FOXP3 within the CD4 gate D) CD127 versus FOXP3 within the CD4 gate E) 
CD25 versus FOXP3 within the CD4 gate
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A combination of antibodies that specifically bind CD4, CD127 (a chain of the IL-7 
receptor), CD25 (a chain of the IL-2 receptor), and FOXP3 was used to define Tregs. All 
CD4+ cells that expressed FOXP3 displayed low levels of CD127 expression and the 
expression levels of these two markers was inversely correlated (Figure 4.1D). All 
CD4+FOXP3+ cells showed low levels of CD127 expression in healthy controls and in HIV 
infected individuals.
Having shown that CD127 and FOXP3 expression identifies a discernable population of 
CD4 cells, the expression of CD25 was examined in this population. The cut-off to define 
CD4 T cells positive for CD25 was determined using an isotype control. (Figure 4.2)
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Figure 4.2: CD4+FOXP3+CD127lo/‘ encompass CD25+ and CD25‘ Tregs: A) Determination of 
CD25+ cut-off within the CD4 gate using a isotype control for FITC B) Cross hairs from A 
copied onto CD25 FITC stained sample C) CD127 versus FOXP3 D) CD25 expression on 
FOXP3+ events from C.
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Using this gating strategy, it was evident that CD4+FOXP3+CD127lo/‘ cells included both 
CD25+ and CD25‘ cells in healthy individuals and HIV infected patients as well (Fig 4.2B). 
In addition it was clear that the levels of CD4+FOXP3+CD127lo/' showed a strong positive 
correlation with CD4+FOXP3+CD25+ (r = 0.7123, p =0.0001).
4.3.2 State of differentiation ofTregs
The enumeration of CD4+ FOXP3+ cells was performed in samples from healthy controls 
and in HIV-1 and HIV-2 subjects to determine the proportion of Tregs that displayed 
surface markers consistent with a naive or memory phenotype. Using CD27 and CD45RO 
markers, naive (CD27+CD45RO'), early differentiated (CD27+CD45RO+) and late 
differentiated (CD27"CD45RO+) Tregs were detected within the CD4+FOXP3+ population. 
The majority of CD4+FOXP3+ cells were found to display an early differentiation 
phenotype in both HIV infected subjects and controls. However a sizeable proportion of 
these cells were also found within the CD27+CD45RO’ population, which is consistent with
------------------- a naive phenotype (Figure 4.3A)^ These naive Tregs had markedly lower levels of CD28
and FOXP3 expression than CD27+CD45RO+ Tregs. This was evident in both HIV infected 
and healthy control samples (Figure 4.3B). Having shown that CD4+FOXP3+ cells represent 
a heterogeneous population ofTregs with both high and low expression of CD28/FOXP3, 
we next determined whether the level of expression could be linked to a functional 
difference by staining with CD39. Activity of CD39 in Tregs has been shown to result in 
suppression of proliferative responses from effector cells. The expression of CD39 was 
significantly higher on CD4+ FOXP3+ CD45RO+ compared to CD4+ FOXP3+ CD45RO' cells 
(Figure 4.3D).
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Figure 4.3: CD4+FOXP3+ represents a heterogeneous population of T cells with a naive 
and memory phenotype. A) Proportion of CD4+FOXP3+ cells are a mix of naive, early 
differentiated and late differentiated cells B) CD39 expression is restricted to CD45RO+ 
cells within the CD4+FOXP3+ cells C) HLA-DR+ cells within the CD4+FOXP3+ gate express 
CD39 D) Comparison of CD39 expression on CD45RO+ and CD45R0' Tregs in healthy 
controls.
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The proportion of naive Tregs (CD4+ CD45RO'CD27+ FOXP3+) were compared between 
HIV-1, HIV-2 and healthy controls. There was no significant difference in the proportion of 
CD4+FOXP3+ cells that displayed a naive phenotype between HIV-1 (median = 25.3(IQR = 
15.5-34.2)), HIV-2 (median =23.2 (IQR = 13.8-37.2)) infected subjects and healthy controls 
(median = 17.75 (IQR = 8.8-17.8)), p=0.12, Figure 4.4B).
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Figure 4.4: Comparison of the proportion of CD4+FOXP3+ T cells that display a naive 
phenotype (CD45RO’CD27+) in HIV-1, HIV-2 and healthy controls. A) Representative 
plots of the distribution of CD4+FOXP3+ in the naive (CD27+ CD45RO'), early differentiated 
(CD27+ CD45RO+), Late differentiated(CD27' CD45RO+), and terminally differentiated 
(CD27+ CD45RO')subsets in HIV-1, HIV-2 and healthy controls. B) Comparison of the 
percentage of CD4+FOXP3+ cells with a naive phenotype in HIV-1, HIV-2 and healthy 
controls. Data was analyzed using the non-parametric Mann-Whitney U test.
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4.3.4 Comparison ofFOXP3 transcript levels and quantification by flow cytometry of 
CD4+FOXP3+ cells:
Real-time PCR measures the total mRNA content of a sample while flow cytometry allows 
the identification of cells expressing particular cell surface and intracellular proteins. As 
yet it is unclear whether the output from these two different methodologies is 
comparable when measuring FOXP3.
In this section FOXP3 transcript (mRNA) levels were measured using reverse transcription 
coupled with real-time PCR and then compared to the number of CD4+FOXP3+ cells 
measured using flow cytometry. FOXP3 transcript levels were normalized against the 
transcript levels of the housekeeping gene beta-D-glucuronidase (GUSB).
Interestingly, we did not find any significant correlation between the percentages of 
FOXP3 positive cells measured by flow cytometry and transcript levels of FOXP3 mRNA in 
our study samples (Figure 4.5A and 4.5B). To determine if aberrant normalization of RT- 
PCR values could account for the discrepancy between RT-PCR and FACS results, the RT- 
PCR data were normalized to a second housekeeping gene, RPLPO. Again no correlation 
between the percent or absolute frequency of CD4+FOXP3+ and transcript levels of FOXP3 
was observed (Figure 4.5C and 4.5D).
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Figure 4.5: Comparison between frequency of CD4+FOXP3+ and transcript levels of
FOXP3 in HIV Patients : A) Percent Treg levels versus FOXP3 transcript levels normalized 
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C) Percent Treg levels versus FOXP3 transcript levels normalized using RPLP0 D) Absolute 
Tregs levels versus FOXP3 transcript levels normalized using RPLP0. Correlations were 
assessed using the non-parametric Spearman's Rank correlation statistic
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4.4 Discussion
Defining the Treg phenotype in HIV disease has remained a contentious subject which 
maybe a contributing factor in the variable conclusions about the role ofTregs in helping 
or hindering the immune system during HIV infection. The observation that FOXP3 
expression in CD4 T cells correlated with the ability of these cells to suppress key immune 
functions in the infected host was a major step forward. (Liu et o i, 2006; Seddiki et oL, 
2006; also see figure 1C). Similarly, the observation that CD127 expression inversely 
correlated with FOXP3 expression provided an additional marker to precisely identify 
these cells (also see figure ID). Using a four-color flow cytometry staining panel, it was 
clear that the use of CD127 and FOXP3 defined a clear population of CD4 T cells that can 
be objectively enumerated (figure 4.1D). The gating strategy that used CD4+CD25+ alone 
to measure Tregs has been shown to be inaccurate since a large proportion of 
CD4+FOXP3+ do not express CD25. Indeed, it has been demonstrated here that the 
CD4+CD127lo/'FOXP3+ population of cells is heterogeneous with regards to the level of 
CD25 expression (Figure 4.2Dy. This was evident in healthy controls as well as HIV 
infected patients. Therefore enumeration ofTregs using CD4+CD127lo/'FOXP3+ represents 
a robust gating strategy to identify the total Treg population.
As interest in FOXP3 expressing Tregs has increased it has become important to develop
better phenotypic and functional markers to define these cells. The analysis in this
chapter revealed that the majority of Tregs in HIV-1, HIV-2 and healthy controls displayed
a cellular phenotype consistent with early differentiated cells characterized by the
simultaneous surface expression of CD45RO, CD27 and high levels of CD28. However,
within these CD4+FOXP3+ cells there was a population of CD45RCT, CD27+ and CD2810 cells
consistent with a naive phenotype. The expression of CD39 was significantly higher on
CD45RO+ Tregs compared to CD45RO- Tregs in HIV infected and in healthy individuals
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which is consistent with previous suggestions that these cells represent activated Tregs. 
Indeed recent reports have shown the CD45RO+ Tregs were highly proliferative when 
compared to CD45RA+ Tregs and homed to different tissues and expressed significantly 
higher levels of CD39 (Miyara et ol., 2009; Booth et ol., 2010). Importantly, the current 
study also found that CD39 expression was present on all HLA-DR+ FOXP3+ cells. Studies 
have shown that HLA-DR expressing Tregs were more potent suppressors of effector 
immune responses (Baecher-Allan et al., 2009). Thus, although we did not assess HLA-DR 
and CD45RO expression in the same panel, the co-expression of HLA-DR on CD39+ FOXP3+ 
cells suggests that they possess a memory phenotype.
The proportion ofTregs with a naive phenotype was similar in HIV infected individuals 
compared to healthy controls, and no differences were seen when comparing HIV-1 and 
HIV-2 subjects. It has been suggested that naive Tregs are highly resistant to apoptosis 
and upon stimulation can quickly convert to a memory phenotype (Booth et al., 2010). 
—This would be an advantageous strategy in a setting of chronic stimulation and nrTayb¥ 
required to counter the high levels of systemic immune activation observed during HIV 
infections.
A comparison of flow cytometry analysis of CD4+FOXP3+ cells and transcript levels of 
FOXP3 using quantitative real-time PCR was also explored. The results of the two 
methods did not correlate which strongly suggest that not all FOXP3 transcripts are 
translated to proteins. This is consistent with a previous study that showed that although 
FOXP3 transcript levels were readily detected in several non-T cell lines, protein 
expression was not present (Yamamoto et al., 2008).
In summary, the results of this chapter show that CD4+FOXP3+CD127lo/' can be used to
measure the total Treg population, which encompasses both CD25+ and CD25' Tregs.
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Furthermore, Tregs exhibit a predominantly memory phenotype (CD27+CD45RO+) but a 
sizeable minority of these cells display a naive phenotype (CD27+CD45R0‘) which maybe 
in a resting state. Finally it was demonstrated that enumeration of Tregs by flow 
cytometry provides values that are different from those of FOXP3 mRNA levels. 
Therefore, caution is warranted in interpreting the results of studies which used FOXP3 
transcript levels in whole blood as a surrogate for total Treg numbers.
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Chapter 5: Comparison of T regulatory cells 
in HIV-1 and HIV-2 infection and 
relationship to viremia and systemic 
immune activation
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5.1 Introduction
Both HIV-1 and HIV-2 infections are found in West Africa but their natural history in man 
differs markedly. The mortality risk in HIV-2 infected individuals is shown to be a mere 
two fold higher when compared to uninfected controls, while HIV-1 infected individuals 
have a 10-20 fold increase in mortality (Jaffar et al.,2004). The two viruses share 
significant homology in their genomes and primarily infect CD4 T cells (Guyader et ol., 
1987). However the majority of HIV-2 subjects maintain high CD4 T cell counts and low or 
undetectable peripheral viremia (Ariyoshi et ol., 2000; Berry et al., 1998, Jaffar et al., 
1997). The reason for the marked difference in plasma viremia between HIV-1 and HIV-2 
(Popper et ol., 1999, Berry et ol. 2002) despite a similar pro-viral load (Ariyoshi et ol., 
1996; Popper et al., 2000) in these subjects is not clear. It may be the result of an 
enhanced immune control of viral replication, defective HIV-2 replicative capacity, or a 
combination of both these mechanisms.
The clinical course of HIV-2 infection has been considered as a unique model of an 
attenuated HIV-1 infection. However, some HIV-2 infected subjects with high viral load 
succumb quickly in a manner indistinguishable from HIV-1 (van der Ende et ol 1996), 
suggesting that the virus may not necessarily be less pathogenic by itself. Thus, 
understanding the immunopathogenic basis of the differences between HIV-1 and HIV-2 
and between HIV-2 progressors and non progressors may be very relevant for the design 
of an HIV-1 vaccine.
Evidence has began to emerge that HIV-2 asymptomatic patients exert more efficient 
immune responses than their HIV-1 counterparts as shown by the presence of strong 
polyfunctional T cell responses expressing the cytotoxic molecules granzymes and 
perforin as well as the cytokines interleukin-2 and interferon-y (Duvall et ol.,2006 2008). 
Innate immune responses notably NK cell activity are greater in HIV-2 subjects with high
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CD4 counts compared with HIV-1 patients with comparable CD4 levels (Nuvor et al.,
2006). Other studies have recently demonstrated that strong HIV-2 specific cellular 
immune responses inversely correlated with plasma viremia (Leligdowicz et al., 2007). 
Together these studies suggest that the immune response is maintained in HIV-2 subjects 
and may account for long term non progression in majority of infection. However, the 
precise reason for their demise in some patients remains unclear. Added to this efficient 
immune response may be an effective immune regulatory mechanism, which hitherto is 
unexplored in HIV-2. The evidence of the role of a suppressive subset of CD4 T cells, 
termed T regulatory cells (Tregs) in viral infection (Reviewed in Rouse et al., 2006) raised 
the possibility that the immune response in HIV-2 infections was more efficiently 
regulated thus preventing immunopathology.
The role of Tregs in HIV pathogenesis has yet to be resolved. Studies have shown that 
Tregs restrain the HIV specific cellular responses needed to control the virus both in the
_____________ periphery (Kinter et al., 2007) and in lymphoid tissues (Kinter ero/., 2007b7 Epple et of7v
2006, Nilsson et al., 2006). Other authors suggest that regulatory function is associated 
with favourable clinical outcome (Kinter etal., 2004) and the presence ofTregs correlates 
with non- progression of disease because of their ability to curtail immune activation, a 
hallmark of HIV infection (Eggena et al., 2005, Ndhlovu et al., 2008, Card et al., 2009 ). It 
is thus unclear whether Tregs play a protective role in HIV-1 infection by limiting the 
intense and harmful hyper-activation that is caused by high levels of replicating virus or 
whether their role is detrimental as they suppress T cell responses making them less 
efficient at controlling HIV replication.
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A comprehensive analysis ofTregs in HIV-2 infection has yet to be conducted. This study 
compares Treg levels in ART naive HIV-1 and HIV-2 infected individuals in West Africa and 
correlates with viral load and immune activation in both patient groups.
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5.2 Materials and Methods:
5.2.1 Study participants
After informed consent was obtained, 86 HIV-1 and 72 HIV-2 antiretroviral naive subjects 
were recruited from a clinic-based cohort at the Medical Research Council (MRC) 
Laboratories in The Gambia. HIV status of the patients was confirmed with HIV-1/ HIV-2 
Murex ICE HIV-1-1.2.0 capture enzyme immunoassay (Murex Diagnostics, Kent, UK). 
Patients were grouped according to CD4+ T cell counts as high (>500 cells/pl) or low (<500 
cells/pl). CD4 counts and viral load were measured as described in the Chapter 3. The 
Gambia Government/ MRC Ethics committee approved the study.
5.2.2 Phenotyping and Enumeration ofTregs
Tregs were measured on freshly taken whole blood using four colour flow cytometry as 
described in Chapter 3 (section 3.4).
5.2.3 Quantitation of soluble 6-2 microglobulin:
Soluble immune activation biomarker p2-microglobulin (P2m) was determined by use of
_____________an automated microparticle EIA (AxSYM system, Abbott Laboratories) as described
(Chapter 3.5).
5.2.3 Statistics
Data was analyzed using Stata software Version 11 (Stata Corp, USA) and Data graphs 
were prepared using Prism (version 5). The non-parametric Kruskal Wallis test was used 
to assess differences between groups. Correlations were tested using Spearmans rank 
correlation co-efficient for non-normally distributed data or Pearsons test for normally 
distributed data. Statistical test results were considered significant if p<0.05.
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5.3 Results
5.3.1 Patient characteristics:
Table 5.1 summarizes the demographic, CD4 and viral load data of HIV-1 and HIV-2 
patients grouped by their absolute CD4 T cell counts.
The median age of all HIV-2 patients was 8.5 years greater than that of HIV-1 subjects. 
There was a high ratio of female: male in all groups, except in the HIV-1 patients with a 
low CD4 count. The viral loads were significantly lower (p=0.0001) in HIV-2 infected 
individuals compared with HIV-1 counterparts (median log viral load: 2.43 versus 4.17). 
HIV-2 subjects within the high CD4 group had a median log VL of 2.00, while that of the 
low CD4 groups it was 3.62 (p=0.0001).
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Characteristic CD4 >50 3 cells/pl CD4< 500 cells/pl
HIV-1
(n=45)
HIV-2
(n=40)
HIV-1
(n=36)
HIV-2
(n=30)
Age in years
35
(30-53)
45
(37-51)
35
(30-43)
42
(30-50)
Female(%) 75 80 54 78
CD4%
27
(23-32)
35
(29-42)
19
(14.5-22)
23
(18-26)
Absolute CD4 count (cells/pl)
700
(580-880)
720
(620-870)
410
(350-440)
330
(270-400)
LogioHIV-RNA (copies/ml)
3.98
(3.18-4.65)
2.00
(2-2.8)
4.49 
(3.85- 5.26)
3.62 
(2.44- 3.95)
Minimum duration of 
Infection(yrs) 2
(1-5)
8
(4-13)
1
(1-3)
1.5
(1-9)
Table 5.1: Patient characteristics. Patients were grouped according to HIV status and 
absolute CD4 T cell counts. Median values are listed for each parameter with the
interquartile ranges in brackets. The minimum duration of infection is the period 
between diagnosis and the time a patient was entered into this study.
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5.3.2. Lower frequency of circulating Tregs levels in HIV-2 than HIV-1 infected subjects 
with a normal CD4+ T cell count.
HIV-2 patients with CD4 T cell counts of >500 cells/pl had significantly lower percentage 
ofTregs than HIV-1 patients (2.1 % (IQR: 1.0-3.4) versus 2.8 %( IQR: 1.9-4.7), p=0.01, 
Figure 5.1A). However, in those with a low CD4 count, there was no significant difference 
between the HIV-1 and HIV-2 patients (4.1% (IQR: 4.1-14.5) versus 3.6% (IQR: 1.8-6.1) 
p=0.1181). Percentage Treg levels in HIV-2 patients with high CD4 counts were also 
significantly lower than HIV-2 subjects with low CD4 T cell counts (median: 2.1 % (IQR: 
1.0-3.4) versus 3.6% (IQR: 1.8-6.1), p=0.03). Similarly, HIV-1 patients with a high CD4 
count had a lower percentage Tregs compared with those with a low CD4 count (median:
2.1 % (IQR: 1.0-3.4) versus 4.1% (IQR: 4.1-14.5), p=0.02)
A comparison of absolute numbers ofTregs in patients with a high CD4 count showed 
that HIV-2 infected patients had significantly lower numbers compared to HIV-1 (medians
16.7 cell/  pi (IQR: 7.9-25.9)) versus 21.6 cells/pl (IQR: 13.1-35.5), p=0.01, Figure 5.1B).
----------------------Similarly HIV-2 patients With low CD4 counts had lower numbers of absolute Treg
compared to HIV-1 patients (medians: 9.1 (IQR: 5.4-20.4) versus 13.2 cells/pl (IQR: 10.4- 
23.7), p=0.04). Comparison of absolute Treg levels showed higher Treg levels in the high 
CD4 group compared to the low CD4 group in both HIV-1 (21.6 cells/pl (IQR: 13.1-35.5) 
versus 13.2 cells/pl (IQR:10.4-23.7), p=0.009 ) and HIV-2 infection (medians 16.7 cell/ pi 
(IQR: 7.9-25.9 versus medians: 9.1 cell/pl (IQR:5.4-20.4), p=0.02).
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Figure 5.1: Percent and absolute levels of Tregs in HIV-1 and HIV-2 patients: A)
Percentage of CD4 T cells expressing CD127lo/' FOXP3+ in HIV-1 and HIV-2 patients with 
CD4 > 500 cells/pl or <500 cells/pl. B) Absolute levels of CD4+CD127lo/' FOXP3+ in HIV-1 
and HIV-2 patients with CD4>500 cells/pl or <500 cells/pl. The medians and interquartile 
ranges are displayed for each group. Data was analyzed using the Mann Whitney U test.
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Similar results were obtained when percentage of CD4+CD25+FOXP3+ was compared 
between HIV-1 and HIV-2 patients (1.51% (IQR: 0.9-2.1) versus 1.02% (IQR: 0.7-1.5), 
p=0.0046). There was very strong correlation between CD4+CD25+FOXP3+ and 
CD4+CD127lo/'FOXP3+ in both HIV-1 (r = 0.9521, p=0.001) and HIV-2 (r=0.9321, p=0.001) as 
well as between CD4+CD127lo/'FOXP3+ and CD4+FOXP3+(Figure 5.2).
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Figure 5.2: Phenotype of T regulatory cells in HIV-1 and HIV-2. A) Representative 
examples of whole blood staining of FOXP3 and CD4, FOXP3 and CD127, FOXP3 and CD25, 
gated on total CD4 T cells. B) Correlation between % CD4+CD25+FOXP3+ and % 
CD4+CD127lo/"FOXP3+ C) Correlation between % CD4+FOXP3+ and % CD4+CD127lo/'FOXP3+. 
Correlations were assessed using the Spearman's rank test.
5.3.3. The proportion of CD4+CD127lo/~F0XP3+ cells inversely correlates with CD4 T cell 
counts in HIV-1 and HIV-2.
The correlation between absolute CD4T cell levels and percent or absolute Treg numbers 
was measured. In both HIV-1 and HIV-2 groups, there was a significant inverse correlation 
between percentage of Tregs and CD4 T cell numbers (HIV-1: r = - 0.3576, p = 0.0011; 
HIV-2: r=-0.3866, p=0.0014, Figure 5.3A). Similarly, the percentage ofTregs was inversely 
correlated with CD4 percentage in HIV-1 (r= -0.4168, p=0.0001) and HIV-2 (r =-0.2779,
p=0.01).
There was a positive correlation between the absolute Tregs count and CD4 T cell count 
in both HIV-1 (r=0.3314, p=0.0015) and HIV-2 infected patients (r=0.3938, p=0.0007) 
(Figure 5.3B).
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Figure 5.3: Correlation between percentage Tregs or absolute Treg count and absolute 
CD4 count A) Percentage of CD4 T cells expressing CD127lo/'FOXP3+ inversely correlates 
with absolute CD4 T cell count in HIV-2 and HIV-1 (B) Absolute count of CD4+CD127lo/‘ 
FOXP3+ cells positively correlates with absolute CD4 T cell count in HIV-2 and HIV-1 
patients. Correlations were assessed using the Spearman Rank test.
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5.3.4. Comparison of immune activation levels and the relationship with Tregs in HIV-1 
and HIV-2
To determine the relationship between Tregs and immune activation, as measured by (3- 
2 microglobulin (32m), their levels were correlated and compared in HIV-1 and HIV-2 
patients with a high CD4 count (absolute CD4> 500 cells/pl) or a low CD4 count ( <500 
cells/pl).
(32m levels were significantly increased in patients with a low CD4 count compared to 
those with a high CD4 count in both HIV-1 (medians: 2180 pg/L versus 2404 pg/L, p = 
0.03) and HIV-2 infection (medians: 2012 pg/L versus 2687 pg/L, p = 0.0024, Fig 5.4A) . 
Indeed, there was a significant negative correlation between 32m and absolute CD4 T 
cells levels in HIV-1 (r=-0.2905, p=0.015) and HIV-2 infected patients (r=0.4879,
p=0.0001).
Comparison of the |32m levels between the HIV-1 and HIV-2 patients with a high CD4 
count showed lower levels in HIV-2 patients but the difference did not reach statistical 
significance (p= 0.08). The levels were similar in HIV-1 and HIV-2 patients with a low CD4 
counts (p=0.39).
The percentage Tregs showed a weak positive correlation with 32m levels in HIV-2 
(r=0.3581, p=0.0326), while there was no correlation observed between P2m levels with 
Tregs in the HIV-1 group (r= 0.1923, p = 0.1595, Figure 5.4B).
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Figure 5.4: Comparison of immune activation in patients with HIV-1 and HIV-2 infection:
A) Comparison of |32m levels in HIV-1 and HIV-2 infection stratified by CD4 counts (>500 
and < 500 cells/pl); Data was analyzed using the Mann- Whitney test B) Correlation 
between p2m levels and percentage Tregs in HIV-1 and HIV-2 infected patients. 
Correlation was assessed using Spearmans Rank test.
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Plasma levels of |32m were positively correlated to viral load in both HIV-1 (r = 0.4414, p=
0.007) and HIV-2 (r=0.3903, p=0.0014) patients, (Figure 5.5A). However the percentage 
Tregs showed a moderate positive correlation with viral load (Fig 5.5B, r=0.4850, 
p=0.0001) in HIV-2 patients, while there was no correlation between Tregs and viral load 
in HIV-1 patients.
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Figure 5.5: Relationship between viral load, immune activation and Treg percentage. A)
Correlation of viral load with plasma level of [32m in HIV-1 and HIV-2 infected patients; B) 
Correlation between viral load and CD4+CD127lo/'FOXP3+ cells in HIV-1 and HIV-2 infected 
patients. Correlations were assessed using the Spearman Rank test.
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5.4. Discussion:
HIV-2 infection predominantly results in long term non-progression and a greater 
proportion of infected individuals maintain high CD4 T cell counts and undetectable viral 
loads compared to those with HIV-1 infection. Immune activation is however a feature of 
both HIV-1 and HIV-2 infection and has been shown to predict progression to AIDS in 
both infections. It is well established that Tregs can modulate systemic and HIV specific 
immune responses though there is divided opinion on whether the suppressive activity of 
these cells is beneficial or detrimental in relation to HIV disease progression. In this study, 
Tregs were enumerated in asymptomatic and progressive HIV-2 and HIV-1 infected 
patients and correlated with markers of disease progression (immune activation and viral 
loads). The results demonstrate that asymptomatic HIV-2 patients have lower 
percentages ofTregs compared to asymptomatic HIV-1 patients or to HIV-2 patients with 
low CD4 T cell counts. However, though asymptomatic HIV-2 patients had lower absolute 
^Tregs compared to patients with asymptomatic HIV-1 infections they were higher than 
HIV-2 patients with low CD4 counts. Furthermore, Tregs were positively correlated with 
immune activation level or viral load in HIV-2 but not in HIV-1 infected patients. 
Importantly these conclusions did not change when we defined Tregs as either 
CD4+CD127lo/'FOXP3+ or CD4+CD25+FOXP3+ since it was shown that two measurements 
were highly correlated (Figure 5.2B).
The controversy over Tregs in HIV infection is in large part due to definition of the cellular 
phenotype, differences in methodologies and differences in patients with regard to level 
of disease progression. In Chapter 4, it was shown that enumeration of Treg using flow 
cytometry does not correlate with FOXP3 transcript levels. Thus, Tregs were enumerated 
by flow cytometry using freshly taken whole blood to minimize any effects of in vitro 
manipulation and selecting CD4+CD127lo/'FOXP3+ as appropriate markers for Treg
identification. Furthermore, HIV-1 and HIV-2 patients were matched by CD4 T cell counts 
which permitted a more detailed analysis between and within the respective infections. 
This study is the most comprehensive comparison of Tregs in HIV-1 and HIV-2 infected 
subjects to date. The only other study that compared Tregs between HIV-1 and HIV-2 
showed no differences between the two infections (Foxall et ol., 2008). However, it is 
important to note that this study measured mRNA levels of FOXP3 as a surrogate for total 
levels of Tregs. Also, the smaller size of the study meant that they were unable to 
categorize patients by CD4 count and thus did not differentiate between asymptomatic 
and progressing HIV-2 infection.
Long term non-progression is a feature of the majority of HIV-2 infections. While this is 
rare in HIV-1 infections, a small proportion of HIV-1 infected patients (elite controllers) 
maintain low viral loads and high CD4 T cell counts similar to those patients with HIV-2 
infection. Recent studies (that used a similar phenotype to measure Tregs by flow 
— cytometry) showed that HIV-1 elite controllers and long term non-progressors had a 
lower percentage of Tregs compared with HIV-1 progressors (Schulze et ol., 2011, Hunt et 
al., 2011). These studies support our findings which suggest that low Tregs are a feature 
of non-progressive HIV disease.
While it was clear that Tregs were significantly lower in HIV-2 asymptomatic infection 
compared to HIV-1, the dynamics of Tregs are similar in both infections. The percentage 
of Tregs increased as CD4 T cell counts declined, while the absolute numbers decreased. 
This suggests that Tregs are depleted during the course of HIV infection but do so at a 
different rate than other CD4 cells. More recent studies of patients with HIV-1 infection 
that have used flow cytometry and the FOXP3 marker to estimate the percentage and 
absolute numbers of Tregs have shown a similar relationship with CD4 T cell counts (Cao
et al., 2009, Bi et ol., 2009, Schulze zur Wiesch et al., 2011). The relative increase in Tregs 
in asymptomatic HIV-1 infection compared to asymptomatic HIV-2 infection may be due 
to increased levels of immune activation (possibly due to higher levels of viral 
replication). Increased immune activation may lead to increased thymic output of Tregs 
or peripheral conversion of conventional CD4 T cells to Tregs as demonstrated previously 
(Walker et al., 2003, Chen et al., 2003). However it is evident that Tregs can themselves 
be infected and depleted by HIV-1 (Oswald-Richter et al 2004). A more recent study 
showed that HIV-1 CXCR4 tropic viruses more efficiently infected Tregs compared to CCR5 
tropic viruses (Moreno-Fernandez et al., 2009). Hence, preferential depletion of non- 
Tregs may also contribute to the percentage increase seen in Tregs at low CD4 T cell 
counts. Whether the HIV-2 virus shows similar cellular tropism remains to be studied.
Immune activation is a key factor in determining progression to disease in both HIV-1 and 
HIV-2. Viral replication damages the host gastrointestinal barriers leading to microbial
________translocation which contributes to increased immune activation in HIV-1 (Brenchley et o/.^
2006). In HIV-2 infection, it is evident that a similar phenomena occurs (Nowroozalizadeh 
et al., 2010). In our study the levels of p-2 microglobulin (|3-2m, a component of the HLA 
Class 1 molecule) were significantly raised in progressive HIV-1 and HIV-2 and positively 
correlated with viral loads. Furthermore, asymptomatic HIV-2 patients had lower levels of 
plasma p-2m compared to HIV-1 patients with similar CD4 T cell counts. The finding that 
Tregs positively correlated with immune activation and viral load in HIV-2 and not HIV-1 
infection suggests that in HIV-2 infection there may be a better balance between 
regulatory and effector responses. This balance may contribute to maintenance of HIV 
specific responses and is explored in Chapter 6.
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In summary, the results from this chapter show that asymptomatic patients with HIV-2 
infections have significantly lower Tregs compared to patients with HIV-1 infection and to 
those with progressive HIV-2 infection. Furthermore, these HIV-2 infected patients also 
displayed lower levels of systemic immune activation suggesting that low Tregs levels are 
a marker of non-progression in HIV infection.
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Chapter 6: Functional characterization of 
effector responses and immune activation 
levels in HIV-1 and HIV-2 asymptomatic
patients
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6.1 Introduction
While a large proportion of HIV-2 infected individuals behave as long term non- 
progressors, it is estimated that this only occurs in less than one percent of HIV-1 
infections (Okulicz et al., 2009, Lambotte et al., 2005). These dichotomous outcomes 
could be due to host genetics, viral factors or the immune response against the 
respective viruses. Hence HIV-2 infection presents an intriguing contrast to HIV-1 
infection and presents an opportunity to understand the factors that lead to successful 
viral control. These attributes would be useful in developing an efficacious HIV vaccine. 
Several studies have provided evidence that T cells that recognize epitopes in the Gag 
region of HIV-1 and HIV-2 are likely to play a role in suppression of viral replication 
(Leligdowicz et al., 2007, Betts et al., 2007). In addition, the degree of polyfunctionality of 
these cells manifest by the ability to produce different effector cytokines such as IL-2, 
TNF-a or IFN-y is inversely correlated with viral load level in HIV-1 infection (Betts et al., 
2006). Direct comparison of HIV-1 and HIV-2 infections suggest that polyfunctional T cells 
‘are“ better preserved in HIV-2 infected patients relative to HIV-1 (Duvall et al 2008). 
Collectively these studies suggest that these responses are important in controlling viral 
replication. However, in the recent Merck trial although the STEP HIV-1 vaccine elicited 
high levels of polyfunctional responses (IFNy and TNF-a, but not IL-2) it failed to protect 
against infection (McElrath eta l 2008). Examination of the possible reasons for the failure 
of this vaccine suggested that increased immune activation elicited by the Adenovirus 
vector 5 (Ad5) used in the vaccine construct may have contributed to higher infection 
rates in the vaccinated group (Buchbinder et al., 2008). This has forced the scientific 
community to re-examine the correlates of protection during HIV infection and decipher 
the relationship between immune activation and HIV specific immune responses.
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It is evident that the immune activation is raised in both HIV-1 and HIV-2 infections 
relative to uninfected healthy individuals and the degree of activation has been shown to 
accurately predict progression to AIDS (Giorgi et al., 1999, Hazenberg et al., 2003, Jaffar 
et al., 2005, Michel et al., 2000). Whether HIV specific immune responses influence 
generalized immune activation (or vice versa) is unclear. In HIV-2 infections this 
relationship remains vague, with one study showing no correlation between HIV-2 Gag 
responses and immune activation (Leligdowicz et al 2010), while another showed a 
positive correlation between activated CD4 T cells and CD4 Gag responses (Foxall et al 
2008).
T regulatory cells (Tregs) are a subset of CD4 T cells that can curtail activation of immune 
cells. While multiple lineages of these cells have been described, CD4 T cells expressing 
the transcription factor FOXP3 has received the greatest attention. The role of Tregs 
during HIV infections remains controversial since it as yet unclear whether their activity is 
helpful or deleterious. Many studies have shown that /n v/'tro Tregs can suppress IFN-y 
production and T cell proliferation in HIV infected individuals, which suggested that Treg 
activity may hamper viral control. However, other accounts suggest that Treg activity was 
beneficial in HIV-1 infection as it inversely correlated with systemic immune activation. 
The results in chapter 5 showed that patients with high CD4 T cell counts had the lowest 
level of Tregs and in addition, HIV-2 patients with high CD4 counts had significantly lower 
Tregs compared to CD4 matched HIV patients. The aim of the work reported in this 
chapter is to determine the relationship between immune activation and specific immune 
responses in HIV-1 and HIV-2 patients with low Treg frequencies.
6.2 Methods
6.2.1 Patients:
HIV-1 and HIV-2 patients found to have low Tregs levels (Chapter 5) were recalled and 
provided an additional aliquot of blood. The viral loads and CD4 levels were tested for all 
patients. PBMC were obtained from all patient samples and used to determine Gag 
specific immune responses as well as levels of activated CD4 and CD8 T cells.
As before, patients that presented with evidence of concurrent infections such as 
malaria or tuberculosis were excluded. Table 6.1 summarizes the characteristics of 
patients recruited to the study.
HIV type Age(yrs)
% Female
CD4% CD4
(cells/jil)
Log Viral 
load 
(copies/ml)
Years
since
diagnosis
HIV-1
(n=23)
35
(30-53)
73 29
(23-32)
620
(530-780)
4.13
(3.22- 
4.34)__
2
(2-4)
HIV-2 
(n= 23)
45
(37-51)
76 36
(30-43)
790
(600-1010)
2.00
(2.00-2.95)
8
(3-15)
Table 6.1: Characteristics of asymptomatic HIV-1 and HIV-2 subjects. All values 
displayed are median values and the interquartile ranges are displayed in brackets. Bold 
values indicate a statistically significant difference between the groups at p<0.05.
6.2.2 Intracellular cytokine assays
The levels of HIV-1 and HIV-2 Gag specific CD4 and CD8 T cells were evaluated using 
overnight stimulation followed by intracellular cytokine staining as described in Chapter 
3, section 3.8.
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6.2.3. Enumeration of activated CD4+ and CD8+ T cells
Activated T cells were defined as co-expression of CD38 and HLA-DR and measured as 
described in Chapter 3, section 3.8.
6.2.4. Depletion assays
To assess whether Tregs inhibited HIV-2 specific and SEB induced responses CD25+ cells 
were depleted and stimulated in parallel with undepleted samples as described in 
Chapter 3, section 3.9
6.2.5. Statistics
Data was analyzed using Stata software Version ll(Stata Corp, USA) and Graphs were 
prepared using Prism (version 5). Unpaired data was analyzed using the non-parametric 
Wilcoxan rank sum test; while paired data was analyzed using the Wilcoxan matched 
pairs test. Correlations were tested using Spearman's rank correlation co-efficient for 
non-normally distributed data. Statistical test results were considered significant if 
p<0.05.
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6.3 Results:
6.3.1 Characteristics of participants
The majority of study participants were predominantly female in both HIV-1 and HIV-2 
infected groups. HIV-2 study subjects had a median age of 45 years which was ten years 
greater than that of median age of HIV-1 subjects. The median CD4 level was significantly 
higher and viral load significantly lower in the HIV-2 group. Seventy three percent of HIV- 
2 subjects had an undetectable viral load and the median time since diagnosis was eight 
years. The HIV-1 patients were more recently diagnosed with median time since diagnosis 
of two years (Table 6.1).
6.3.1 HIV-2 subjects elicit higher polyfunctional responses to Gag antigen
The percentages of CD4 and CD8 T cells expressing IL-2, IFN-y and CD107a after HIV
specific or SEB stimulation were determined and background levels (CD28/CD49d control) 
were subtracted (Figure 6.1).
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Figure 6.1: Intracellular cytokine responses after overnight stimulation. A) CD4 cells 
expressing IL-2, IFN-y B) CD8 T cells expressing IFN-y and CD107a Gag or SEB.
CD4 T cells secreted IL-2, IFN-y or both after HIV Gag or SEB stimulation. CD8 T cells
responding to HIV Gag peptides up regulated IFN-y and co-expressed CD107a, a marker 
that is expressed on cells that are degranulating.
CD4+ and CD8+ T cells producing IFN-y after HIV Gag stimulation were observed in both 
HIV-1 and HIV-2 subjects (Table 6.2). The percentage of positive CD4 and CD8 T cells in 
the unstimulated control were subtracted from those in the peptide and SEB stimulated 
cultures. There was no difference in the median levels of IFN-y secreting CD4 (HIV- 
1:0.129%, HIV-2 : 0.139% ,p =0.8802) or CD8 (HIV-1: 0.21%, HIV-2: 0.26%, p=0.6130) T 
cells between HIV-1 and HIV-2 in the unstimulated controls. A positive response was 
defined as that which was above the background value.
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All HIV-2 patients tested showed a positive response, by either CD4+ or CD8+ T cells to 
Gag peptides compared with 78% in HIV-1 infected individuals (p=0.001). In addition, a 
higher proportion of HIV-2 subjects (75%) had both a CD4 and CD8 T cell response 
compared with only 21% in the HIV-1 infected group (p=0.01). PBMC from both HIV-1 and 
HIV-2 showed a CD4 and CD8 T cell responses after stimulation with the positive control 
SEB.
HIV type Total
responders
CD4
responders
only
CD8
responders
only
CD4+CD8+
responders
HIV-1 18/23 8/23 4/23 5/23
(78%) (33%) (17%) (21%)
HIV-2 21/21 3/21 2/21 16/21
(100%) (15%) (10%) (75%)
Table 6.2: Summary of HIV-1 and HIV-2 patients showing a positive Gag response by T 
cell subsets
After stimulation with gag peptides the percentage of Gag specific CD4+IFNy+cells 
(median: HIV-1: 0.001, HIV-2: 0.1, p=0.001), CD4+IFNy+ IL-2+cells (median: HIV-1:0, HIV-2: 
0.02, p=0.0001) and CD4+IL-2+ cells (median: HIV-1:0, HIV-2: 0.02, p=0.003) were 
significantly higher in the HIV-2 infected patients compared to the HIV-1 patients (Figure
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6.2A). Similarly, the levels of CD8+IFN-y+ staining cells were significantly higher in the HIV- 
2 group compared to HIV-1 after Gag stimulation (p=0.0035, Figure 6.2B)
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Figure 6.2: Comparison of Gag specific responses in HIV-1 and HIV-2. A) CD4 T cell and
B) CD8 T cell responses in HIV-1 and HIV-2 subjects. The Mann-Whitney U test was used 
to measure differences between groups.
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6.3.2. Comparison of T cell activation between HIV-1 and HIV-2 patients
Immune activation is a central feature of both HIV-1 and HIV-2 infections. To determine
the immune activation levels within the T cell compartment in the study samples co­
expression of cyclic ADP ribose hydrolase (CD38) and human leukocyte antigen (HLA-DR) 
on CD4 and CD8 T cells was measured using six-colour flow cytometry as described in the 
methods sections. Activated cells were defined as those co-expressing HLA-DR and CD38 
(Figure 6.3A).
The median percentage of CD8+CD38+HLA-DR+ were significantly lower in HIV-2 patients 
compared to HIV-1 subjects (HIV-1: 9.48% (IQR: 7.17-15.48), HIV-2: 5.3% (IQR: 4.38-5.76); 
p=0.002). Similarly, the proportion of CD4+CD38+HLA-DR+ cells in the HIV-1 patients 
(median: 2.6% (IQR: 1.92-4.53%) was significantly higher than the HIV-2 patients (median 
1.67 % (IQR: 1.19-1.81), p = 0.001, Figure 6.3). The median percentage of CD4 T cells 
expressing either CD38 (HIV-1:41.7 HIV-2:36.7, p=0.1423) or HLA-DR (HIV-1: HIV-2:, p= 
0.4484 ) only, were similar between the two groups of patients. Similarly, the median 
percentage of CD8 T cells expressing either CD38 (HIV-1:31.26 HIV-2:27.82, p=0.6400) or 
HLA-DR (HIV-1:6.96 HIV-2: 4.825, p=0.2373) only, were similar (data not shown). The 
percentage of CD4+CD38+HLA-DR+ cells was positively and significantly correlated with 
CD8+CD38+HLA-DR+ in HIV-1 infected patients (r=0.8248, p=0.001) and HIV-2 patients 
(r=0.6529, p=0.002, figure 6.3B and C).
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Figure 6.3: Comparison of T cell activation in HIV-1 and HIV-2 asymptomatic patients. A)
Comparison of CD4+CD38+HLA-DR+ and CD8+CD38+HLA-DR+ cells in HIV-1 and HIV-2 
patients. Horizontal bars represent the median values and interquartile ranges are 
indicated. Correlation of CD4+CD38+HLA-DR+ and CD8+CD38+HLA-DR+ in HIV-1 (B) and HIV- 
2(C). The rs values indicate the correlation statistic using the spearman rank test.
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6.3.3. Relationship of activated T cells and Tregs in HIV-1 and HIV-2 
The percentage of CD4+CD38+HLA-DR+ or CD8+CD38+HLA-DR+ T cells was correlated with 
those of Tregs as defined by CD4+CD127lo/‘FOXP3+ markers in HIV-1 and HIV-2 infected 
patients. The percentage of CD4+CD38+HLA-DR+ cells showed a modest positive 
correlation with percentage Tregs in HIV-2 infected subjects (r = 0.5531, p=0.01, Figure 
6.4A). Similarly the percentage of CD8+CD38+HLA-DR+ was also positively correlated with 
the percentage Tregs in HIV-2 infected patients (r=0.4736, p=0.03, Figure 6.4B). There 
was no correlation observed between Tregs and CD4+CD38+HLA-DR+ or CD8+CD38+HLA- 
DR+ in the HIV-1 patients.
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Figure 6.4: Relationship between Tregs and activated T cells. A) Correlation of 
percentage CD4+CD127lo/FOXP3+ and CD4+CD38+HLA-DR+ cells in HIV-1 and HIV-2 
infected patients B) Correlation of percentage CD4+CD127lo/'FOXP3+ and CD8+CD38+HLA- 
DR cells in HIV-1 and HIV-2 infected patients. Correlation was assessed using the 
spearman rank test.
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6.3.4 Relationship of immune activation and HIV specific immune responses in HIV-2 
infection
Having determined the levels of immune activation and HIV specific immune responses in 
the HIV-1 and HIV-2 patients, we aimed to determine whether the two were correlated. 
No correlation was observed between the percentage of CD4+CD38+HLA-DR+ and 
CD4+IFNy+ cells in HIV-2 (r=-0.3289, p=0.1258) or HIV-1 infection (r=0.2451, p=0.2123). No 
correlation was observed between percentage CD8+CD38+HLA-DR+ and CD8+IFNy+ cells in 
either the HIV-1 (r= -0.3745, p=0.09) or HIV-2 (r=-0.2283, p=0.1563) infected patients 
(Figure 6.4).
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Figure 6.5: Correlation between immune activation and HIV Gag specific IFN-y
responses. A) CD4+IFN-y+ responses and percentage CD4+CD38+HLADR+ cells B) CD8+IFN- 
Y+ responses and CD8+CD38+HLADR+ cells in HIV-1 and HIV-2 infected patients.
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6.3.5 HIV-2 specific Tregs inhibit HIV specific Gag responses
Having determined the magnitude of responses in CD4 and CD8 T cells we sought to 
ascertain whether Tregs from HIV-2 infected subjects were functional. PBMCs from seven 
HIV-2 patients that had previosuly responded to a pool of HIV-2 Gag peptides were used 
for the Treg depletion and ICS assays.
The characteristcs of the patients selected for the depletion experiments are summarized 
in Table 6.3.
Donor
Subset of 
cells 
responding 
to gag CD4%
CD4
(cells/pl)
Viral
load(copies/mL)
yrs since 
diagnosis(years)
1 CD4/CD8 41 980 673 17
2 CD4/CD8 31 780 100 16
3 CD4 35 1040 100 15
4 CD8 52 1410 100 20
5 CD4 26 520 100 10
6 CD4/CD8 42 1090 290 12
7 CD4 31 790 100 10
Table 6.3: Characteristics of patients used for depletion experiments
Analysis of the CD25+ fraction obtained from PBMCs showed that >95% of these cells
expressed FOXP3 and they were all CD4+. Depletion resulted in a median 42% (range= 30
-74%) reduction in the levels of CD4+FOXP3+ cells in the PBMCs (Figure 6.6A) and a 99%
reduction of CD4+CD25+ cells. Removal of Tregs resulted in a modest increase in
percentage of IFN-y from CD4 T cells (Figure 6.6C, p=0.06). Of note, Treg depletion did
not increase the levels of CD4+IL-2+ cells in any of the donors. Depletion of CD25+ cells
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resulted in increased CD8 T cell responses after Gag stimulation from all patients (Figure
6.6 D, p=0.01). These were predominantly polyfuntional in nature as the CD8 T cells 
expressed both IFN-y and showed evidence of degranulation as measured by CD107a 
expression (Figure 6.6B).
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Figure 6.6: Effects of Treg depletion on percentage of IFN-y secreting cells after Gag 
and SEB stimulations. A) Representative plot of undepleted and CD25 depleted CD4 T 
cells B) Comparative plots of CD8 and CD4 T cell responses from whole PBMCs and CD25 
depleted samples C) Comparison of percentage IFN-y producing CD4 T cells in undepleted 
and CD25 depleted PBMC after HIV-2 Gag stimulation D) Comparison of CD8 T cells co­
expressing CD107a and IFN-y in undepleted and CD25 depleted PBMC after HIV-2 Gag 
stimulation
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6.4. Discussion
In Chapter 5, it was demonstrated that HIV-2 asymptomatic patients harboured 
significantly lower Treg levels than HIV-1 patients and these correlated with viral load and 
immune activation in the HIV-2 patients only, suggesting more efficient immune control 
than those in HIV-1 infection. To explore the relationship between immune activation and 
HIV specific immune responses , asymptomatic HIV-1 and HIV-2 patients with preserved 
CD4 T cell counts (>500 cells/pl) and low Treg levels were selected. The majority of HIV-2 
patients displayed characteristics of long-term non progression as determined by a high 
CD4 T cell count, undetectable viral load and a median time since diagnosis of at least 
eight years. In contrast, HIV-1 patients were more recently diagnosed and despite high 
CD4 T cell counts, had a median viral load two logs higher than that of HIV-2 patients. 
This suggests that while the HIV-2 patients are true non-progressors, the majority of HIV- 
1 patients in this study will eventually progress to AIDS.
It is well established that immune function is better preserved in HIV-2 asymptomatic 
patients than in HIV-1 patients. Studies have demonstrated that the magnitude, breadth 
and polyfunctionality of T cell responses are greater in HIV-2 patients than HIV-1 (Duvall 
et al., 2006, 2008, Lopes etal., 2003). Furthermore, the magnitude of T cell responses has 
been shown to inversely correlate with viral load, suggesting these cells are effective in 
controlling viral replication (Jaye et al., 2004, Leligdowicz et al., 2007). In support of these 
findings, HIV-2 patients displayed greater magnitude and polyfunctionality of both CD4 
and CD8 T cells compared to HIV-1 subjects in this study. Previous studies measuring CD8 
T cell responses and total PBMC responses did not show differences between IFN-y levels 
between HIV-1 and HIV-2 infected patients (Jaye et al., 2004, Ondondo et al., 2008). The 
varying results maybe as a result of differences in methodologies such as the use of 
ELIspots as opposed to Intracellular Cytokine staining and flow cytometry.
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A high level of immune activation has been shown to be associated with disease 
progression in both HIV-1 and HIV-2. Immune activation probably increases the 
availability of target cells for infection as well as inducing greater replication of the virus 
in latent pools. In chapter 5, it was shown that immune activation was positively 
correlated with viral load in both infections and was marginally lower in asymptomatic 
HIV-2 infected subjects than in HIV-1 infected subjects. We now show that in 
asymptomatic HIV-2 patients had significantly lower activation of CD4 and CD8 T cell 
compared to HIV-1 patients. While a previous study had demonstrated lower activation 
of CD8 T cells in HIV-2 subjects compared to HIV-1 infected individuals, they failed to 
detect differences in the levels of activated CD4 T cells (Hanson et al., 2005).
In Chapter 5 a positive correlation between Tregs and immune activation in HIV-2 
patients but not HIV-1 patients was found. Now we show that Tregs are also positively 
correlated with activated CD4 and CD8 T cells in the HIV-2 group only. This suggests that 
in HIV-2 infection increasing immune activation is balanced by a proportional Treg 
response, while this balance is lost in HIV-1 infection.
The results show that the features of long-term nonprogression in HIV-2 are low levels of 
Tregs which control immune activation and preserve immune function. It is pertinent to 
compare the results here with similar studies conducted in the so called HIV-1 'elite 
controllers'. These patients maintain a low viral load and high CD4 count that is 
reminiscent of the majority of HIV-2 infections. A study by Owen et al., (2010) showed 
that elite HIV-1 infected controllers had lower levels of activated T cells but similar levels 
of Tregs when compared to HIV-1 non-controllers. In another study HIV-1 controllers had 
high levels of activated T cells and low levels of Tregs compared to HIV-1 progressors 
(Hunt et ol., 2011). The latter study suggested that these low Treg levels allowed effective
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adaptive responses but also higher systemic immune activation. The differences between 
the conclusions of these studies maybe due to the phenotype used to enumerate Tregs. 
While both studies used CD38 and HLA-DR co-expression to define activated cells, neither 
used FOXP3 as part of their signature to measure Tregs.
Treg activity may play a pivotal role in determining the outcome of infection for the 
suppressive capacity of these cells has been associated with favourable outcome in both 
HIV-1 and SIV infections (Kinter et al., 2004, Karlsson et al., 2011). Similarly, we found 
that Tregs were functional in HIV-2 infected patients and that removal of Tregs resulted 
in increased IFN-y secretion from CD4 T cells and IFN-y and degranulation of CD8 T cells. 
These findings suggest that Tregs do control HIV-2 specific immune responses and may 
impact on the control of viral replication.
In conclusion, the results from this chapter show that HIV-2 patients with the 
characteristics of long-term non progressors have low Treg levels and maintain high HIV-2 
specific immune responses accompanied by low levels of activation in the CD4 and CD8 T 
cell compartment. The findings also reinforce the idea that a useful balance between 
Tregs and immune activation exists in HIV-2 infections, but is conspicuously absent in 
HIV-1 infections.
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Chapter 7: Immune Reconstitution 
Inflammatory Syndrome (IRIS): delayed 
reconstitution of T regulatory cells?
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7.1. Introduction
The Immune Reconstitution Inflammatory Syndrome (IRIS) results from an exuberant 
immune response against residual antigens (paradoxical IRIS) or against viable pathogens 
(unmasking IRIS) in HIV infected patients commencing antiretroviral therapy (Shelburne 
et al., 2005, French et al., 2004, Lawn et al., 2005). While most cases of IRIS develop in 
response to Mycobacteria, a number of other pathogens (such as cytomegalovirus and 
cryptococcal infections) have also been associated with the development of IRIS 
(Murdoch et al., 2007).
The reported incidence of IRIS varies and a recent meta analysis showed a range from 
10% to 32% for all cause IRIS (pathogen unidentified) (Muller et al., 2010).The peak 
incidence of IRIS occurs 2 to 8 weeks after ART initiation, and both paradoxical and 
unmasking IRIS are more common in patients with a low CD4 T cell count prior to starting 
ART (Valin et al.,2010, Ratnam et al., 2006). While IRIS often has a benign course, it can 
cause considerable morbidity and occasionally be fatal (Lawn et al., 2009).
The etiology of IRIS remains enigmatic, including its immunological mechanism and 
predictors. Increased proliferation and production of IFN-y from highly activated CD4 T 
cells towards tuberculin, and increased levels of KIR- y6+ T cells were observed in TB- IRIS 
compared to non-IRIS ART controls (Bourgarit et al., 2006 & 2009). A more recent study 
demonstrated that IRIS patients displayed higher levels of HLA-DR+, Ki-67+, PD-1+ and 
effector memory subsets of CD4 T cells compared to non-IRIS controls (Antonelli et al., 
2010). Similarly, using a model of Mycobacterium avium (M. avium) challenge in 
lymphopenic mice, Barber et al.(2010), demonstrated the onset of symptoms consistent 
with IRIS after injection of exogenous CD4 T cells. Together these studies suggest that 
aberrant activation of reconstituted CD4 T cells is the underlying cause of IRIS.
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T regulatory cells (Tregs) are committed suppressors of the immune system. While 
multiple subtypes have been described, the best characterized remain the natural Tregs 
which originate from the thymus (Khattri et al., 2003), but found to be also induced in the 
periphery. Tregs function by suppressing the secretion of cytokines and proliferative 
responses by a variety of immune cell types (Sakaguchi et al., 2010) in response to 
microbial and self-antigens (Sakaguchi et al., 2004, Suffia etal., 2006). The role of Tregs in 
the development of IRIS remains contentious, as a recent study showed no differences in 
Treg levels between patients developing TB-IRIS and asymptomatic patients (Meintjes et 
al., 2008) while another study found that Tregs from patients with IRIS due to M. avium 
were less suppressive than Tregs from non-IRIS ART controls (Seddiki et al., 2009).
The clinical symptoms of IRIS are consistent with a dysregulated and exuberant immune 
response which suggests the absence of effective immune regulation. Using a prospective 
longitudinal study design we have focused on the dynamics of Tregs following the start of 
ART and tested the hypothesis that (all-cause) IRIS results from a relative delay in the 
reconstitution of FOXP3 positive T regulatory cells. In addition, we assessed whether 
baseline plasma cytokines could predict the occurrence of IRIS after initiation of ART. The 
results from this study argue against a significant role for Treg levels, for neither the 
proportion nor absolute number, were predictors of IRIS.
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7.2. Materials and Methods:
7.2.1 Clinical
In a prospective observational cohort conducted at the MRC Laboratories in The Gambia, 
Seventy- one consecutive ART naive adult African patients, who had a nadir CD4 count < 
200 and were scheduled to commence ART were asked for informed consent prior to 
inclusion in the study. Fifty eight of these patients were singly infected with HIV-1, 9 with 
HIV-2 only, while 4 were dually infected with both HIV-1 and HIV-2. Patients were 
screened for TB at baseline by reviewing symptoms and chest radiographs. They were 
encouraged to return to the clinic anytime they developed new symptoms. On their 
scheduled visits at 2, 4, 8, 12, and 24 weeks post ART initiation, patients were asked 
specific questions about IRIS prior to seeing a physician. These included questions as to 
whether they had a fever, night sweats, cough, headache, nausea, abdominal pain, 
weakness, visual problems, skin lesions, or any swelling. The physicians assessed each 
patient's likelihood of having IRIS, and all cases were subsequently reviewed and 
classified as IRIS based on the criteria outlined by Haddow et al. (2009, see Appendix)-------
7.2.3 Laboratory
Patients had viral load, full blood count and lymphocyte subsets determined as part of 
their routine medical care at baseline, 12 and 24 weeks. In addition, patients donated 
blood for flow cytometry analysis at baseline and the routine follow-up visits at 4, 8, 12 
and 24 week visits. Plasma was stored at -209C.
The study was approved by the Gambian Government/ MRC Ethics Committee.
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7.2.4 Enumeration of Tregs using FACS staining of whole blood
Fresh whole blood (150 pi) was stained within 6 hours using conjugated monoclonal 
antibodies to CD25-FITC, CD4-PerCP, CD3-PE (Becton Dickinson, USA) and FOXP3-APC 
(Clone: PCH101, Ebiosciences, USA) as described in Chapter 3, Section 3.4.
7.2.5 CD4 T cell counts and viral load measurements:
Enumeration of CD4 levels (CD4% of total CD3 T cells) and viral loads were determined at 
baseline and follow-up visits as described in Chapter 3.
7.2.6 Measurement of plasma cytokine levels:
Plasma levels of IL-2, IL-6, IL-10, IL-12, IL-13, IL-17, TNF-a, MIP-lp and IFN-y were 
measured at baseline using a single Bioplex assay (Bio-Rad, USA) on undiluted plasma as 
described in Chapter 3.
7.2.7 Analysis
Patients were classified into IRIS and non-IRIS groups. Patients who interrupted ART > 1 
week, or stopped ART before 12 weeks, were excluded from the immunological analysis.
Longitudinal proportions and absolute levels of Tregs were analyzed using generalized___
estimating equations (equal correlation structure) adjusting for age, sex, ethnicity and 
viral loads. Cross-sectional analyses of baseline response were compared between the 
IRIS and non-IRIS groups adjusted for the same possible confounders as mentioned 
above. Tests with a p-value < 0.05 were considered statistically significant. All analyses 
were performed in Stata (version 11) and figures were drawn using Prism (version 5).
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7.3 Results
7.3.1 Incidence of IRIS in the study cohort
Of 80 patients enrolled after informed consent, 71 (89%) completed more than 12 weeks 
of ART without an interruption of greater than one week. One patient was found to have 
CD4 count >800 cells/pl twice on repeat baseline testing, and was subsequently taken off 
ART. Four patients were lost to follow-up before 12 weeks, and 2 patients interrupted 
ART for 1 month. Three patients died, of whom two had interrupted ART for more than 
four weeks prior to death without IRIS symptoms recorded at the last visit. One patient, 
in whom IRIS could not be excluded, died after 8 weeks on ART.
Of the 71 patients included in the analysis, 21 (30%) developed symptoms consistent with 
IRIS using the criteria set out by Haddow et al (2009). Fifteen (71%) of these patients 
were classified as cases of unmasking IRIS.
IRIS patients typically had highly advanced disease and commenced therapy with a 
significantly lower nadir CD4 count than non-IRIS patients (60 versus 120 cells/pl, p= 
0.03). Two of the 9 HIV-2 infected subjects and one of the 4 dually infected subjects 
developed IRIS.
However, the IRIS group also showed a significantly greater increase in absolute CD4 T 
cells levels compared with non-IRIS group six months after commencement of 
antiretroviral therapy ( 150 versus 100 cells/pl, p=0.04). All subjects showed excellent 
responses to treatment and 92% of patients had an undetectable viral load at the end of 
the follow-up period (Table 7.1 and Figure 7.1).
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Table 7.1. Patient characteristics
All IRIS Non-IRIS P value
N (%) 71 20(28%) 51(72%)
Male 25 (35%) 5 (24%) 20 (39%)
Age in years
(median)
41 39 43 ns
CD4 nadir (median) 
Cells/|il
100
(30-160)
60
(20-130)
120
(45-180)
0.03
CD4 increase in 6 mo
(median) Cells/pl
120
(70-205)
150
(120-330)
100
(50-180)
0.01
HIV type
1 58 (82%) 17(85%) 41(80%) ns
2 9 (13%) 2 (10%) 7(14%) ns
dual 4(6%) 1(5%) 3(6%) ns
VL < 100 copies/ml 65 (92%) 18(90%) 47(92%)
Ethnicity
Mandinka 28 (39%) 7(30%) 21(41%) ns
Wolof 9 (13%) 2(10%) 7(14%) ns
Fula 8 (11%) 3(10%) 5(10%) ns
Jola 8 (11%) 3(10%) 5(10%) ns
Other 18 (25%) 5 (20%) 13(25%) ns
ART 24wk 61 (86%) 19 (95%) 42(69%) ns
IRIS= Immune reconstitution inflammatory syndrome 
ADE= Adverse drug effects
VL= Viral load, <100= undetectable within first 9 months of ART 
ART= Antiretroviral therapy
ART 24wk= No interruption in ART use >3 days over 24 weeks
128
ns= not significantly different, p>0.05
The majority of patients that developed IRIS showed symptoms within the first month 
after initiation of ART (16 of 20 (80%)). The median duration of IRIS symptoms was 49 
(IQR: 28-91) days. Pathogens were rarely identified and the lung and skin or mucosal 
surfaces were involved in most cases (Table 7.2). Eight of the twenty patients who 
developed IRIS had developed TB, for which they were treated before commencing ART. 
Of note there were nine HIV-2 infected subjects that were included in this study and two 
of these developed IRIS.
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Age Sex HIV CD4 Nadir IRIS IRIS Duration Predominant Organ nadir VL CD4 increase
(yrs) (cells/pl) (week) (days) copies/ml) (cells/pl)
40 F 1 50 2 91 Skin <100 50
38 F 2 130 3 110 Pulmonary <100 150
29 F 1 220 2 42 Pulmonary <100 330
21 F 1 70 2 66 Renal/Pulmonary <100 390
38 F 1 20 12 296 Skin 985 110
33 F 1 100 4 14 Pulmonary <100 120
35 M 1 10 1 91 Pulmonary <100 130
30 F 11 130 1 32 Skin <100 150
40 F 1 20 4 49 Skin <100 210
31 F 1 90 4 40 Pulmonary <100 240
44 F 1 130 8 88 Pulmonary <100 280
35 F 1 100 2 70 Skin <100 300
26 F 10 4 49 Skin <100 330
47 M 11 60 2 28 Pulmonary <100 350
39 F 1 10 2 14 Pulmonary <100 410
33 F 1 80 3 30 Skin 5014 580
46 F 1 50 3 67 Pulmonary <100 60
44 M 1 140 2 13 Skin <100 80
45 M 1 10 12 84 Lymph <100 90
41 M 1&2 30 7 35 Lymph <100 90
Table 7.2: Features of IRIS patients.
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Figure 7.1: Median CD4 levels (A) and viral loads (B) at different times after initiation of 
ART in IRIS and non-IRIS group. The vertical bars represent the interquartile range.
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7.3.2 T regulatory cell reconstitution in patients with and without IRIS
In Chapter 5 (Figure 5.2C) it was shown that the levels of CD4+FOXP3+ and CD4+CD127lo/‘
FOXP3+ cells were highly correlated in both HIV-1 and HIV-2 patients. As an automatic
processing tool was available to determine CD4+FOXP3+ events we chose to define Tregs
as CD4 T cells co-expressing the transcription factor FOXP3. Using this tool it was possible
to objectively quantify Treg levels in all patient samples. The output from the algorithm
was consistent and comparable to manual analysis (Jeffries et al., 2008). The gating
strategy employed to enumerate Tregs as a percentage of total CD4 T cells is shown in
Figure 7.2.
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scatter B) CD4 versus FOXP3 and C) CD25 versus FOXP3
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No significant difference was observed in percentage Treg levels between the IRIS and 
non-IRIS groups before initiation of ART (Month 0). Tregs expressed as a percentage of 
total CD4 T cells declined after ART initiation, a trend which was evident in both patient 
groups (Figure 7.3A). Indeed, comparison of Treg levels at baseline (median: 15.5%) and 
six months (median: 6.6%) after commencement of ART showed a significant reduction in 
all patients (p= 0.002). Similarly, there was no significant difference when comparing 
levels of absolute Tregs at baseline or six months after ART in any of the groups (Figure 
7.4B). These trends were observed regardless of the definition of Tregs (CD4+FOXP3+ 
versus CD4+CD25+FOXP3+).
133
25-|
20 -
+co
ft 15'o
LL
8  io-
non-IRIS
-6- IRIS
1 P
B
1 2
Months on ART
non-IRIS
IRIS
40-i
30-
3 , 20 -co___
LL
10-
0 1 2 3 6
Months on ART
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7.3.4 Baseline cytokines and chemokines do not predict IRIS
Plasma cytokine levels were measured at baseline to determine whether these could be 
used to predict the onset of IRIS. The levels of IL-12, IL-13, and IL-17 were below the limit 
of the assay in all patients tested. Plasma levels of IL-2, IL-6, IFN-y MIP-lp, IL-10 and TNF- 
a were comparable in both groups (Table 7.3). There was no significant correlation 
observed between the levels of CD4+FOXP3+ cells and any of the cytokines measured.
Category Cytokine (pg/ml)
IL-2 IL-6 IFN-y MIP-ip TNF-a IL-10
Non-IRIS 0.765
(0-12.27)
7.4
(3.16-
10.83)
10.65
(4.57-34.66)
73.65
(54.11-
124.91)
0
(0-1.67)
2.84
(1.21-4.22)
IRIS 4.86
(0-28.74)
11.16
(3.84-
25.47)
27.11
(4.57-
243.78)
72.52
(56.49-
98.21)
2.1
(0-4.17)
4.38
(1.45-9.98)
Table 7.3: Cytokine profile of patients before commencement of therapy. The median 
and interquartile ranges are shown.
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7.4 Discussion
The definition of IRIS remains elusive, both as a clinical phenotype with imprecise case 
description and as an immunological phenomenon which occurs during the massive 
overhaul of the immune system as people start ART. Several case definitions have been 
proposed for TB-IRIS (Meintjes et ol., 2008) and all-cause IRIS. The most recent all-cause 
IRIS case definition was used in this study which has been validated before (Haddow et 
a l, 2009).
The incidence of IRIS (28%) was comparable with similar studies in South Africa and 
Mozambique and lower than that reported in Senegal (Letang et al., 2011, Muller et o l, 
2010). In our study IRIS patients had a significantly lower nadir CD4 T cell count and 
showed a greater recovery of CD4 T cell count compared with the non-IRIS group. These 
results re-affirm that a low CD4 T cell count at the time of initiating ART is a risk factor 
for the development of IRIS (Letang et a l ., 2011, Grant et ol, 2011, Ratnam et ol, 2006, 
Jevtovic et ol, 2005)
The majority of IRIS cases developed within the first month after starting on ART. In 
addition the IRIS patients showed a higher recovery of CD4 T cells compared to the non- 
IRIS group. These findings emphasize the need for commencing ART early and for close 
monitoring of HIV infected patients after the start of ART. Unique to this study were 9 
patients infected with HIV-2; two of these patients developed IRIS. This emphasizes the 
point that in HIV-2 infected individuals who progress to AIDS, the clinical course after 
treatment may mirror that of HIV-1 infected individuals.
Understanding the immunopathogenesis of IRIS remains a challenge. Higher levels of 
immune activation prior to commencement of ART have been identified as a risk factor 
for development of IRIS. Hence, it was hypothesized that there was a difference of Treg
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dynamics in patients commencing ART that could distinguish IRIS from non-IRIS cases. 
Although we noted lower levels of absolute Tregs at baseline in those patients who would 
develop IRIS the differences were not significant and the percentage of Tregs were similar 
in both groups of patients. The proportion of Tregs in all patients declined steeply after 
the initiation of ART, which is consistent with the results of a recently published study 
(Montes e ta l,  2010).
There were no clear differences in the trend of percentage or absolute Tregs between 
IRIS and non-IRIS groups. However the data was highly variable thus it cannot be ruled 
out that Treg dynamics within the first month after initiation of ART may influence the 
development of IRIS. Future studies would require more intensive sampling during the 
first few weeks after initiation of ART.
The results are consistent with a previous study comparing Treg levels in TB patients 
commencing ART, which similarly showed no significant differences in the percentage of 
Tregs at the time of IRIS presentation versus non-IRIS cases two weeks post ART 
treatment (Meintjes et al., 2008). While neither the TB-IRIS study nor our study included 
functional assays, a cross-sectional study on 8 patients with M. avium related IRIS 
identified high numbers of Tregs (Seddiki et al 2009). However these Tregs were unable 
to suppress the secretion of pro-inflammatory cytokines IFN-y, TNF-a and IL-6 in vitro, 
suggesting that a defect of regulatory T cells may indeed contribute to IRIS. It is therefore 
plausible that despite high frequencies of Tregs, IRIS may result from inadequate 
suppressive function of these cells. Further studies that can quantitate Treg function at 
ART initiation and prior to development of IRIS may clarify whether Treg dysfunction 
rather than changes in numbers indeed contributes to IRIS.
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Higher levels of pro-inflammatory cytokines before resumption of ART have been linked 
to a greater risk of developing IRIS (Reviewed by Sereti et al., 2010). Even though there 
were higher median levels of IL-6 and IFN-y in the IRIS group in our study compared to 
the non-IRIS group at baseline, these differences were small and did not predict the 
development of IRIS.
Heterogeneity within the diagnostic category of IRIS, including unmasking of active 
infection, response to residual antigens, non-antigen driven immune responses, and 
involvement of different organ systems, further limits the interpretation of our findings 
as these could represent substantially different immunologic pathways. Although 
research on IRIS is limited by the mutually reinforcing challenges of inadequate clinical 
case definitions and a lack of biomarkers related to its pathogenesis, recent data focused 
on M. tuberculosis related IRIS suggest that this syndrome depends on interactions 
between the residual components of M. tuberculosis, which serve as stimuli for innate 
immune^or specific T cell responses, the partially reconstituted cellular immune 
response, and incomplete regulation of the reconstituted immune system. IRIS can occur 
within days of commencement of ART, prior to witnessed increases in CD4 counts, which 
suggests a role for other components of the immune system. The strong granulomatous 
response commonly seen in IRIS (Lawn et al., 2009) has led to the hypothesis that the 
granulomas result from macrophages resuming normal function with the decrease in viral 
load (Van den Berg et al., 2006). This is supported by findings that in vitro gpl20  
stimulation of monocyte-derived macrophages is sufficient to induce profound changes in 
macrophage gene expression patterns (Cicala etal., 2002).
In summary the results of this study show that neither Treg frequencies nor cytokine 
levels predict the onset of IRIS. Further investigation is required to assess Treg function to
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determine whether these cells influence innate and adaptive responses that contribute to 
the development of IRIS.
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Chapter 8: Final Discussion
HIV infection remains a significant cause of morbidity and mortality around the world 
despite concerted efforts to curtail its spread. The introduction of ART to AIDS endemic 
areas has reduced the mortality associated with HIV infections but it is estimated that for 
every one person started on ART therapy another five new infections occur (UNAIDS 
Global Report 2010). This highlights the need for an effective vaccine that prevents the 
spread of HIV infection. Recent positive developments from the RV144 vaccine trial have 
encouraged researchers and this suggests that it is possible to develop an efficacious 
vaccine (de Souza et ol., 2009). However, a major roadblock in developing a vaccine is an 
incomplete understanding of the immunology of HIV infection. Our knowledge of the 
correlates of immune protection in HIV-1 remains incomplete due to the scarcity of 
patients that control the replication of their virus who are available for study. The studies 
of HIV-2 infection have the potential to provide valuable insight into mechanisms of non- 
progressjon, since unlike HIV-1, the majority of HIV-2 infected patients efficiently control 
viral replication and maintain the integrity of their immune system (Berry et al., 
2002,Leligdowicz et al., 2007, Nuvor et al., 2006, Duvall et al., 2006). Both infections are 
characterized by chronic immune activation (Michel et al., 2002, Leligdowicz et al., 2008), 
high levels of which can accurately predict progression to AIDS (Jaffar et. al 2005). Hence, 
understanding the factors that contribute to control of immune activation would assist in 
the development of an efficacious vaccine.
T regulatory cells are potent suppressors of cellular activation which suggests that they 
may limit the ability of HIV virus to infect and replicate since they preferentially target 
activated T cells. However, the suppressive activity of Tregs has also been shown to 
diminish HIV specific immune responses (Andersson et al., 2005, Aandahl et al 2004,
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Kinter et. al 2004, 2007, Weiss et al., 2004). Hence, there is continued debate on whether 
the Treg activity is beneficial or detrimental in HIV disease progression. While there have 
been many studies describing these cells in HIV-1 infections, there has been only one 
previous study which attempted to quantify and compare Tregs in HIV-1 and HIV-2 
infection (Foxall et al 2008). This study used FOXP3 mRNA as a surrogate marker for these 
cells. In my work I attempted to define and compare the role of Tregs in HIV-1 and HIV-2 
infected individuals by studying their phenotype, frequencies and functional 
characteristics.
A major caveat in the study of Tregs in HIV infection has been the lack of an appropriate 
cellular phenotype to identify these cells. Other studies used FOXP3 mRNA levels as a 
surrogate for total Treg levels but in most cases these failed to correlate them with cell 
frequencies (Kinter et ol., 2005, Yamamoto et ol., 2008). In Chapter 4 of this thesis, it was 
shown that CD4 T cells that expressed FOXP3 also exhibited CD127lo/‘ co-expression and 
that these cells were heterogeneous^in their expression of CD25. Furthermore, 
CD4+FOXP3+ cells were predominantly at an early differentiation stage (as determined by 
co-expression of CD45RO and CD27) but there was also a population of FOXP3 cells with a 
naive phenotype (CD45RO'CD27+) in healthy donors and HIV infected subjects. This 
proportion of naive Tregs was similar in HIV-1, HIV-2 and healthy individuals, which 
suggests that it is a true population and not the result of activation induced FOXP3 
expression as suggested by others.
I also attempted to assess whether the transcript levels of FOXP3 measured by real time 
PCR and number of Tregs (measured by flow cytometry) were correlated in HIV infected 
patients. The results clearly showed that the measurement from the two methods did not
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correlate and suggests that new methodologies used to enumerate Tregs should be 
carefully evaluated.
In some cases HIV-2 infection can lead to disease progression similar to that observed in 
HIV-1 infection. The second study performed measured Tregs as a percentage of total 
CD4 T cells or as absolute numbers to determine their relationship with disease 
progression. This comparison clearly demonstrated that HIV-2 asymptomatic patients 
with high CD4 counts had significantly lower levels compared to HIV-1 patients matched 
by CD4 T cell counts or HIV-2 patients who had evidence of disease progression. The 
asymptomatic patients had the lowest levels of immune activation and median viral 
loads. The findings suggest that low percentage of Treg levels are a feature of non­
progression and such HIV-2 patients had been infected for longer than HIV-1 patients and 
HIV-2 progressors. Furthermore, Treg levels positively correlated with immune activation 
and viral loads in HIV-2 infections only. These results suggest that increasing activation as 
-a result of viral replication in HIV-2 may be countered by an increased induction of Tregs. 
The lack of this relationship in HIV-1 patients suggests that the balance between effector 
and regulatory mechanisms is impaired. The majority of HIV-1 infections are 
characterized by higher levels of viral replication compared to HIV-2. This results in 
chronic stimulation of the immune system and increased levels of immune activation. 
This may account for the higher levels of Tregs observed in asymptomatic HIV-1 infection 
and would negatively influence HIV specific immune responses. In contrast, the lower 
levels of Tregs in HIV-2 infection may be due to lower immune activation as a result of 
reduced viral replication.
The immune function in HIV-2 asymptomatic patients has been shown to be better 
preserved compared to that in HIV-1 infections. To explore the balance between immune
activation and HIV-2 specific immune responses, patients with low Tregs were selected 
for further studies in parallel with HIV-1 patients. The comparison of CD4 and CD8 HIV 
specific immune responses revealed superior magnitude and polyfunctionality in HIV-2 
patients compared to HIV-1. Furthermore, the levels of activation in the CD4 and CD8 T 
cell compartments were also significantly lower in HIV-2 group. This suggests that long 
term non-progression is associated with low levels of Tregs, preserved and polyfunctional 
T cell responses and low activation levels. These results are further strengthened by 
similar studies conducted on HIV-1 elite controllers which have been show them to have 
low levels of immune activation, low Treg numbers and a high level of HIV specific 
polyfunctional T cell responses ( Schulze zur Weisch et al 2011; Owen et al 2010).
IRIS develops in some patients commencing ART therapy. It was hypothesized that 
delayed reconstitution of Tregs may be a factor in the development of IRIS. In agreement 
with previous reports, IRIS patients had lower CD4 counts at their nadir and a better 
— reconstitution of CD4 cells than the non-IRIS group. Surprisingly though, there was no 
clear differences observed in the increase during treatment of Tregs in patients who 
developed IRIS and those who did not. Furthermore, measurement of baseline cytokine 
levels or Tregs did not discriminate the two groups. IRIS encompasses a broad range of 
clinical symptoms and the heterogeneity in the IRIS classification may have contributed to 
the negative finding. While it was not possible to explore functional characteristics of the 
cells that contribute to IRIS or Tregs, further studies are warranted to decipher which 
correlates will identify patients at risk of developing IRIS.
Understanding the factors associated with non-progression during HIV infection are 
essential for designing a viable vaccine. HIV-2 presents a physiologically relevant human 
model to assist in this endeavour. This study has shown that HIV-2 non-progression is
associated with lower levels of Tregs, preserved immune function and low immune 
activation. Further studies are warranted to compare the function of Tregs between HIV- 
2 progressors and non-progressors. Furthermore, better correlates of IRIS are required so 
as to be able to identify patients at risk before initiation of ART.
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APPENDIX
Clinical guidelines for defining IRIS cases as outlined by Haddow et ol 2009.
Paradoxical IRIS 
Clinical criteria
1. Temporal relationship: ART initiation must precede clinical deterioration
2. One of the following:
a. Worsening of an infectious or inflammatory condition that was recognized and ongoing 
at the time of ART initiation, following a clinical response to appropriate treatment
b. Deterioration with atypical or exaggerated clinical, histological, or radiologic findings in 
terms of severity, character of inflammatory response, rapidity of onset, or localizationa
c. Recurrence of an episodic infectious or inflammatory condition, worse than episodes 
within 1 year preceding ART in terms of frequency, severity, or response to therapy
Exclusion of other causes 
Worsening not explained by
1. Expected clinical course of underlying condition, given current therapy and the 
susceptibility profile of the organism
2. Drug toxicity
3. Other infection or inflammatory condition
4. Withdrawal of previously effective therapy
5. Failure of antiretroviral treatment: presumptive, based on either non-adherence or 
resistance to ART, or confirmed, based on VL assay if available.
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Unmasking IRIS
Clinical criteria
1. Temporal relationship: ART initiation must precede clinical deterioration
2. New onset of symptoms of an infectious or inflammatory condition after initiation of 
ART
3. Consistent with the presence of preexisting causative pathogen or antigen at the time 
of starting ART
4. Either of the following:
a. Onset within 3 months after initiating ART
b. Atypical or exaggerated clinical, histological, or radiological findings in terms of 
severity, character of inflammatory response, rapidity of onset, or localization 
Exclusion of other causes
Event not explained by
1. Expected clinical course of another condition
2. Drug toxicity
3. Newly acquired infection, based on clinical history or other evidence
4. Failure of antiretroviral treatment: presumptive, based on either non-adherence or 
resistance to ART, or confirmed, based on VL assay if available
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T regulatory Cell Study
Patient Consent Form
I have read, or had read to me, the information sheet for this study. I understand 
what it says, and what being in the T regulatory cell study means for me. I had a 
chance to ask questions about the study, and had them answered.
I understand that the information regarding me, including my medical status and the 
results of studies done on blood samples, will remain confidential.
I understand that part of the blood samples that I provide will be stored for possible 
future tests.
I understand that if I get sick during the study period, I can go to the clinic where 
study staff is providing care, and be examined and treated for free.
I understand that I am free to take part in the study or refuse, and that I can 
withdraw from the study at any time, and without giving any reason. Deciding not to 
take part or to withdraw from the study will not affect the care that I am normally 
entitled to.
Please check one of the following:
 I am in other research studies.
 I am not in other research studies.
Signature or thumb print of volunteer:___________________________
Date: |___ |___ | / 1___| _ |  / 1___ |___ |___ |___ |
O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O
This form has been read by / 1 have read the above t o ________________________
------------------         (write name of volunteer)-------
in a language that he/she understands. I believe that he/she has understood what I 
explained and that he/she has freely agreed to take part in the study.
Signature of field worker:
Name of field worker:
Date: |___|___| / 1___|___| / 1___|___|___|___|
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T Regulatory Cell Study
Information for Participants
What is the problem with HIV? HIV is a chronic infection, which in some cases badly damages the 
immune system. At the moment there is no cure for the disease but we can slow down progress of 
the disease.
What are T regulatory cells? T regulatory cells are important in controlling the response of your 
body to infection. This ensures an appropriate response such that any inflammation is reduced
What is this study about? The object of this study is to understand the role of T regulatory cells in 
HIV infected individuals.
Why are we asking you to participate? As a member of the HIV cohort we have been monitoring 
your progress. We would like to invite you to join the study so we can see whether T regulatory cells 
are helpful in keeping you healthy.
What happens if you agree to participate? Your participation in this study is entirely voluntary. 
Being in this study is not likely to help or harm you in any significant way. You will not be paid to 
participate in this research study. We are not asking to bleed you in addition to what you have 
consented for when joining the cohort. A small portion of the 15ml (3 teaspoons) of blood taken from 
you will be used for routine monitoring of your immune system (CD4 count and viral load). We will 
use the remainder of the blood to measure the number of T regulatory cells and other tests to check 
they are functional. If there is any remaining blood it will be stored for later, as yet unspecified, 
scientific tests focused on immunity to HIV.
Questions? Please feel free to ask any questions you want at any time during the study. All 
personal data collected for this study will be treated as confidential information. Information (other 
than the name or other identifying information) gathered in the course of medical care at MRC may 
be used in the development or answering of research questions related to medical care, and to 
inform public health officials and policy makers about health-related conditions in the Gambia.
You are free to leave the study at any time you so wish. This will not affect your access to normal 
medical care. You should not feel obligated to agree to participate. Your questions should be 
answered clearly and to your satisfaction. If you are willing to help us with this study, we would like 
ou to sign the consent form.
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